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Résumé	
Ce	travail	de	thèse	s’intéresse	aux	anticorps		dirigés		contre		l’apolipoprotéine		A-1	(anti-apoA-1	IgG),	la	
principale	fraction	protéique	des	particules	de	HDL	cholestérol.		
Jusqu’à	présent,	des	travaux	scientifiques	fondamentaux	ont	établi	le	rôle	des	anti-apoA-1	IgG	en	tant	
que	 molécules	 pro-inflammatoires	 et	 pro-athérogènes,	 associées	 à	 une	 mortalité	 accrue	 dans	 des	
modèles	murins.	 Par	 ailleurs,	 des	 travaux	 cliniques	préliminaires	ont	démontré	 la	 valeur	pronostique	
indépendante	 des	 anti-apoA-1	 IgG	 dans	 la	 maladie	 cardiovasculaire	 (CV)	 dans	 des	 populations	 des	
patients	 atteints	 de	 maladies	 auto-immunes,	 des	 patients	 à	 risque	 CV	 élevé	 ou	 post	 infarctus	 du	
myocarde.		
En	utilisant	des	données	de	la	“Cohorte	Lausannoise”	(étude	CoLaus),	une	cohorte	populationnelle	de	
plus	de	6500	habitants	de	la	ville	de	Lausanne,	ce	travail	de	recherche	s’est	décliné	en	3	objectifs	:	1)	
mieux	 comprendre	 la	 prévalence	 des	 anti-apoA-1	 IgG	 dans	 la	 population	 générale,	 2)	 examiner	
l’association	entre	anti-apoA-1	IgG	et	la	prévalence	et	facteurs	de	risque	de	la	maladie	CV	3)	examiner	
les	 déterminants	 génétiques	 des	 anti-apoA-1	 IgG	et	 établir	 leur	 valeur	 pronostique	pour	 la	mortalité	
globale	et	les	évènement	coronariens	dans	la	population	générale.	
Concernant	 les	 deux	 premiers	 objectifs,	 nos	 résultats	 publiés	 dans	 la	 revue	 «	Thrombosis	 and	
Haemostasis	»	 révèlent,	 pour	 la	 première	 fois,	 que	 des	 taux	 élevés	 d’anti-apoA-1	 IgG	 sont	 présents	
dans	 environ	 20%	 des	 individus	 dans	 la	 population	 générale.	 Ils	 sont,	 par	 ailleurs,	 associés	 à	 une	
prévalence	 accrue	 de	 maladies	 CV	 dans	 la	 population	 générale,	 indépendamment	 des	 facteurs	 de	
risque	CV	traditionnels.	Par	ailleurs,	dans	le	sous-groupe	des	sujets	atteints	de	maladie	CV	dans	le	passé	
(prévention	secondaire),	nous	mettons	en	évidence	une	association	des	anti-apoA-1	IgG	avec	un	profil	
pro-inflammatoire,	 témoigné	 par	 un	 taux	 de	HDL	 cholestérol	 diminué,	mais	 aussi	 par	 des	 valeurs	 de	
protéine	C-réactive	de	haute	sensibilité	et	d’acide	urique	élevées.	
En	partant	de	ces	observations,	nous	avons,	par	 la	suite,	 investigué	une	prédisposition	génétique	à	 la	
présence	 des	 anti-apoA-1	 IgG.	 Nos	 résultats	 publiés	 dans	 le	 journal	 «	Frontiers	 in	 Immunology	»	
démontrent	que	des	taux	élevés	d’	anti-apoA-1	IgG	sont	associés	à	des	polymorphismes	du	gène	FCRL3,	
gène	 impliqué	 dans	 la	 susceptibilité	 aux	maladies	 auto-immunes	 chez	 l’être	 humain.	 Dans	 le	même	
manuscrit,	nous	montrons	que	la	présence	des	anti-apoA-1	IgG	est	associée	de	manière	significative	et	
indépendante	à	la	mortalité	toutes	causes	confondues	dans	la	population	générale.		
Finalement,	concernant	le	lien	entre	anti-apoA-1	IgG	et	maladie	coronarienne,	nous	avons	récemment	
démontré	 que	 les	 anti-apoA-1	 IgG	 seraient	 davantage	 des	 prédicteurs	 indépendants	 de	 nouveaux	
événements	coronariens	et	que	cette	association	serait	modulée	par	un	polymorphisme	fonctionnel	du	
gène	du	 récepteur	CD14.	 Ses	observations	 sont	publiés	dans	 le	 journal	«	Arteriosclerosis,	 Thrombosis	
and	Vascular	Biology	(ATVB)	»	sous	le	titre	«	Impact	of	CD14	polymorphisms	on	anti-apolipoprotein	A1	
IgG	related	coronary	artery	disease	prediction	in	the	general	population	».		
D’un	point	de	vue	de	santé	publique,	ces	résultats	innovants,	obtenus	dans	une	étude	populationnelle	à	
grande	 echelle,	 sont	 prometteurs	 concernant	 le	 rôle	 des	 anti-apoA-1	 IgG	 non	 seulement	 comme	 un	
nouveau	facteur	de	risque	CV	indépendant,	mais	également	en	tant	que	cible	spécifique	potentielle	de	
thérapies	immuno-modulatrices	avec	des	implications	cliniques	futures.		
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Association between anti-apolipoprotein A-1 antibodies and 
 cardiovascular disease in the general population
Results from the CoLaus study
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1Department of Internal Medicine, University Hospital of Lausanne, Lausanne, Switzerland; 2Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, 
Geneva University Hospitals, Geneva, Switzerland; 3Department of Human Protein Sciences, Faculty of Medicine, University of Geneva, Geneva, Switzerland; 4Department of 
 Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland; 5Division of Cardiology, Foundation for Medical Researches, Department of Medical 
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Summary
We aimed to determine the association between autoantibodies 
against apolipoprotein A-1 (anti-apoA-1 IgG) and prevalent cardiovas-
cular (CV) disease (CVD) as well as markers of CV risk in the general 
population. Cross-sectional data were obtained from 6649 subjects 
(age 52.6 ± 10.7 years, 47.4 % male) of the population-based CoLaus 
study. CVD was defined as myocardial infarction, angina pectoris, per-
cutaneous revascularisation or bypass grafting for ischaemic heart dis-
ease stroke or transient ischaemic attack, and was assessed according 
to standardised medical records. Anti-apoA-1 IgG and biological 
markers were measured by ELISA and conventional automated tech-
niques, respectively. Prevalence of high anti-apoA-1 IgG in the general 
population was 19.9 %. Presence of anti-apoA-1 IgG was significantly 
associated with CVD [odds ratio 1.34, 95 % confidence interval 
(1.05–1.70), p=0.018], independently of established CV risk factors 
(CVRFs) including age, sex, hypertension, smoking, diabetes, low and 
high-density lipoprotein cholesterol levels. The n=455 (6.8 %) study 
participants with a history of CVD (secondary prevention subgroup) 
presented higher median anti-ApoA-1 IgG values compared with sub-
jects without CVD (p=0.029). Among patients in the secondary pre-
vention subgroup, those with positive anti-apoA-1 IgG levels had 
lower HDL (p=0.002) and magnesium (p=0.001) levels, but increased 
uric acid and high-sensitivity C-reactive protein levels (p=0.022, and 
p<0.001, respectively) compared to patients with negative anti-
apoA-1 IgG levels. In conclusion, anti-apoA-1 IgG levels are indepen-
dently associated with CVD in the general population and also related 
to CV biomarkers in secondary prevention. These findings indicate that 
anti-apoA-1 IgG may represent a novel CVRF and need further study 
in prospective cohorts.
Keywords
Anti-apolipoprotein A-1 antibodies, cardiovascular disease, high-
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Atherosclerosis and Ischaemic Disease
Introduction
Despite considerable advances having been made in its prevention, 
diagnosis and treatment, cardiovascular disease (CVD) remains 
the leading cause of death in the Western world. Major discoveries 
in the pathophysiology of CVD over the last 30 years have shifted 
the long-standing paradigm that held CVD primarily as a lipid-
 related metabolism disorder, to the current view of an immune-
mediated inflammatory disease, where humoral autoimmunity 
may play an important role (1, 2).
Different lines of evidence indicate that autoantibodies may 
represent a novel, independent cardiovascular risk factor (CVRF), 
(3–5) not only in their potential role as biomarkers for risk stratifi-
cation but also as mediators of CVD, amenable to targeted thera-
peutic strategies (6).
Among autoantibodies possibly related to CVD, those directed 
against apolipoprotein A-1 (anti-apoA-1 IgG), the major protein 
fraction of high-density lipoproteins (HDL), are of particular in-
terest. During the last decade, numerous translational studies have 
examined the mechanisms underpinning the role of anti-apoA-1 
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IgG in inflammation (7, 8) and atherogenesis (9–12). In addition, 
preliminary clinical studies have shown encouraging results re-
garding the association and prognostic value of anti-apoA-1 IgG 
for CVD in subjects with autoimmune diseases (9–11, 13, 14), sub-
jects at high CV risk (15–17), or in secondary prevention (18–23).
Nevertheless, the prevalence of anti-apoA-1 IgG and their as-
sociation with CVD or markers of CV risk in the general popu-
lation have not yet been examined. Therefore, the purpose of our 
current study was manifold: first, to investigate the prevalence and 
association of anti-ApoA-1 IgG with CVD in the general popu-
lation. The second objective was to study the possible association 
of anti-ApoA-1 IgG with both established and emergent CV 
markers, in the general and secondary prevention populations. 
The third objective was to investigate the possible connection be-
tween anti-apoA-1 IgG and serum magnesium concentrations, as 
anti-ApoA-1 IgG have shown to be associated with a higher basal 
heart rate after myocardial infarction (MI) (23) through activation 
of L-type calcium channels (24, 25), tightly regulated by intracellu-
lar magnesium concentrations (26).
Materials and methods
Study population and design
We obtained cross-sectional clinical and biological data from the 
CoLaus study, a population-based observational study investigating 
cardiovascular disease (CVD) and risk factors in a random sample 
of 6733 subjects, aged between 35 and 75 and living in the city of 
Lausanne, Switzerland. Recruitment began in June 2003 and ended 
in May 2006. All participants of the CoLaus study were eligible for 
participation in the current study and were included in the analysis. 
The study was approved by the Institutional Ethics Committee of 
the University of Lausanne and informed consent was obtained 
from all participants. A detailed description of the study design and 
sampling procedures has been reported elsewhere (27).
All participants attended the outpatient clinic of the University 
Hospital of Lausanne in the morning, after an overnight fast. Data 
were collected from each participant by trained field interviewers 
in a single visit lasting about 60 minutes (min).
Blood pressure and heart rate were measured three consecutive 
times using an automated sphygmomanometer (Omron® 
HEM-907, Matsusaka, Japan) and the average of the last two 
measurements was used. Hypertension was defined as a systolic 
blood pressure (SBP) ≥ 140 mmHg and/or a diastolic blood press-
ure (DBP) ≥ 90 mmHg and/or presence of anti-hypertensive treat-
ment. Diabetes mellitus was defined as fasting plasma glucose ≥7.0 
mmol/l and/or oral or insulin antidiabetic treatment. Body weight 
was measured in kilograms to the nearest 0.1 kg using a Seca® scale 
(Hamburg, Germany) and height was measured to the nearest 5 
mm using a Seca® height gauge (Hamburg, Germany). Body mass 
index (BMI) was defined as weight/height2. Metabolic syndrome 
was identified according to the NCEP-ATP III criteria (28) in sub-
jects presenting with at least three of the following components: 1) 
SBP>130 mm Hg or DBP>85 mm Hg or treatment; 2) waist 
size>88 cm if female or >102 cm if male; 3) HDL-C<1.30 mmol/l 
for women or <1.03 mmol/l for men; 4) TG>1.7 mmol/l or lipid-
lowering drug treatment; and 5) glucose>5.6 mmol/l or antidia-
betic drug treatment. Aggregate CV risk was assessed using the 
Systematic COronary Risk Evaluation (SCORE) algorithm. Auto-
immune disease was defined as history of rheumatoid arthritis or 
systemic lupus erythematosus, independently of treatment status.
Prevalent CVD was defined by the presence of myocardial in-
farction (MI); angina pectoris; percutaneous revascularisation or 
bypass grafting for ischaemic heart disease; stroke or transient is-
chaemic attack and assessed according to standardised medical 
records (27).
A venous blood sample (50 ml) and a spot urine sample were 
collected from each participant under fasting conditions. The ana-
lytical procedures and clinical assays used for determining serum 
and urine biological markers are available in Suppl. Table 1 (avail-
able online at www.thrombosis-online.com). The urinary frac-
tional excretion of magnesium was calculated according to the fol-
lowing formula (29):
FeMg = (UMg x SCr) / (0.7 × SMg x UCr),
where UMg= urinary magnesium (mmol/l), SCr= serum creati-
nine (µmol/l), SMg= serum magnesium (mmol/l) and UCr= uri-
nary creatinine (µmol/l). Glomerular filtration rate (GFR) was es-
timated by the simplified Modification of Diet in Renal Disease 
(MDRD) prediction equation:
GFR (ml/min/1.73 m2) = 186 × (SCr)-1.154 × (Age)-0.203 × (0.742 if 
female),
where SCr= plasma creatinine concentration in mg/dl, and age= 
years.
Assessment of autoantibodies against 
 apolipoproteinA-1
Anti-apoA-1 IgG were measured as previously described (20, 21), 
using the CoLaus study (2003–2006) serum aliquots that had been 
previously frozen and stored at –80 °C. Maxisorp plates (NuncTM, 
Roskilde, Denmark) were coated with purified, human-derived 
delipidated apolipoprotein A-1 (20 µg/ml; 50 µl/well) for 1 hour 
(h) at 37 °C. After being washed, all wells were blocked for 1 h with 
2 % bovine serum albumin (BSA) in a phosphate buffer solution 
(PBS) at 37 °C. Patient samples were also added to a non-coated 
well to assess individual non-specific binding. After six washing 
cycles, a 50 µl/well of signal antibody (alkaline phosphatase-conju-
gated anti-human IgG; Sigma-Aldrich, St Louis, MO, USA), di-
luted 1:1000 in a PBS/BSA 2 % solution, was added and incubated 
for 1 h at 37 °C. After washing six more times, phosphatase sub-
strate p-nitrophanylphosphate disodium (Sigma-Aldrich) dis-
solved in a diethanolamine buffer (pH 9.8) was added and incu-
bated for 20 min at 37 °C (Molecular DevicesTM Versa Max). Op-
tical density (OD) was determined at 405 nm, and each sample 
was tested in duplicate. Corresponding non-specific binding was 
subtracted from mean OD for each sample. The specificity of de-
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tection was assessed using conventional saturation tests by West-
ern blot analysis (20, 21).
Elevated levels of anti-apoA-1 IgG were set at an OD cut-off of 
OD>0.64, corresponding to the 97.5th percentile of a reference 
population of 140 healthy blood donors. In order to limit the im-
pact of inter-assay variation, we calculated an index consisting in 
the ratio between sample net absorbance and the positive control 
net absorbance × 100. The index value corresponding to the 97.5th 
percentile of the normal distribution was 37. Accordingly, to be 
considered as positive (presenting elevated anti-apoA-1 IgG lev-
els), samples had to display both an absorbance value >0.64 OD 
and an index value ≥37.
Sample size and power calculation
Based on previous published studies on healthy blood donors (21) 
we assumed an expected prevalence of anti-apoA-1 IgG in healthy 
subjects devoid of CVD of 5–10 %. Taking into account the CVD 
rate in CoLaus (455 events or 6.8 %) and a two-sided alpha of 5 %, 
our study had 80 % power to detect an odds ratio (OR) of anti-
apoA-1 IgG for CVD at OR=1.51.
Statistical analysis
Univariate analysis of continuous variables was performed using 
the Student’s t-test or the non-parametric Mann-Whitney test to 
account for non-parametric distributions, and results were ex-
pressed as mean ± standard deviation (SD) or as median (inter-
quartile range), as appropriate. Analysis of discrete variables was 
performed using Chi-square test and results were expressed as 
number of participants and (percentage).
Multivariate analysis was performed using logistic regression 
adjusting for age, sex, hypertension, diabetes, smoking, low-den-
sity (LDL) and high-density lipoprotein cholesterol (HDL). Results 
were expressed as OR and 95 % confidence interval (CI). All ana-
lyses were performed using STATA 13.0 (Stata Corp, College 
Station, TX, USA).
All conducted analyses were predefined at the moment of study 
conception and disclosed when applying for funding. Contrary to 
confirmatory studies where correcting for multiple testing is 
required, for exploratory analyses correction for multiple testing 
increases the type II error for non-null associations (30), leading to 
reduced statistical power and precluding the identification of po-
tentially interesting associations (30–32). Thus, for testing pre-
planned associations of anti-apoA-1 IgG with specific and interde-
pendent CV features in the current study, a two-tailed p<0.05 was 
considered statistically significant.
Results
Association between anti-apoA-1 IgG and CVD, 
 independently of established CVRF
The flowchart and objectives of the study are summarised in 
▶ Figure 1. N=6194 (93.2 %) study participants were devoid of 
baseline CVD (primary prevention subgroup), while n=455 
(6.8 %) were in secondary prevention. The distribution of raw op-
tical density (OD) values for anti-apoA-1 IgG in the sample is il-
lustrated in Suppl. Figure 1 (available online at www.thrombosis-
online.com).
As described in ▶ Table 1, elevated levels of anti-apoA-1 IgG 
were present in 1323 out of 6649 (19.9 %) study subjects. In the 
general population, the prevalence of clinical CVRF did not differ 
between subjects with presence vs absence of anti-apoA-1 IgG. 
The same observation was true both in the primary and the sec-
ondary prevention subgroups. Furthermore, we did not find any 
significant difference in CV drugs rates depending on presence vs 
absence of anti-apoA-1 IgG. Among study subjects, n=154 had a 
history of autoimmune disease (either rheumatoid arthritis or sys-
temic lupus erythematosus). We observed no association between 
history of autoimmune disease and elevated levels of anti-apoA-1 
IgG in the population (▶ Table 1).
Prevalence of CVD in the general population was significantly 
associated with presence vs absence of anti-ApoA-1 IgG (8.3 % vs 
6.5 %, respectively, p=0.018). Indeed, patients with history of CVD 
had higher median OD values for anti-ApoA-1 IgG than subjects 
without (OD: 0.412, interquartile range (IQR): 0.273–0.661 vs 
0.395, IQR: 0.253–0.589, p=0.029).
Translated into OR, elevated levels of anti-ApoA-1 IgG were as-
sociated with a 1.3-fold increased risk for prevalent CVD; an as-
sociation which remained unchanged after adjustment for estab-
lished CVRFs, including age, sex, hypertension, diabetes, smoking, 
LDL and HDL cholesterol. Alternatively, there was a 15 % risk in-
Figure 1: Study 
flowchart and end-
points. Anti-apoA-1 
IgG, autoantibodies 
against apolipoprotein 
A-1; CVD, cardiovascu-
lar disease; CV, cardio-
vascular.
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Anti-apoA-1 IgG
Sample size, n (%)
Age, years
Male sex, n (%)
CVD, n (%)
Hypertension, n (%)
Diabetes, n (%)
Metabolic syndrome, n (%)
Current smoking, n (%)
Autoimmune disease
Heart rate, bpm
Systolic BP, mmHg
Body mass index, kg/m2
CV risk (SCORE)
CV drugs
 Aspirin
 Statins
 Beta blockers
 Calcium channel blockers
 IEC/ARB
 Diuretics
General population 
(n=6649)
Negative
5326 (80.1)
52.7 ± 10.8
2527 (47.5)
345 (6.5)
1851 (34.8)
351 (6.6)
1196 (22.5)
1422 (26.7)
116 (2.2)
68.0 ± 9.7
128 ± 18
25.8 ± 4.5
0.6 (0.2–2.2)
855 (16.0)
581 (10.9)
284 (5.3)
161 (3.0)
408 (7.7)
120 (2.2)
Positive
1323 (19.9)
52.3 ± 10.7
626 (47.3)
110 (8.3)
456 (34.5)
81 (6.1)
309 (23.4)
358 (27.1)
38 (2.9)
68.1 ± 10.3
128 ± 18
25.8 ± 4.7
0.6 (0.2–2.1)
191 (14.4)
123 (9.30)
81 (6.1)
43 (3.2)
88 (6.7)
22 (1.7)
P-value
0.201
0.933
0.018
0.844
0.537
0.484
0.791
0.133
0.656
0.471
0.853
0.165
0.148
0.088
0.259
0.668
0.211
0.184
Primary prevention subgroup 
(n=6194)
Negative
4981 (80.4)
52.1 ± 10.6
2336 (46.9)
.0 (0.0)
1619 (32.5)
294 (5.9)
956 (19.6)
1347 (27.0)
105 (2.1)
68.1 ± 9.6
128 ± 18
25.7 ± 4.4
0.6 (0.2–1.9)
677 (13.6)
432 (8.7)
198 (4.0)
113 (2.3)
339 (6.8)
98 (2.0)
Positive
1213 (19.6)
51.6 ± 10.6
556 (45.8)
0 (0.0).
382 (31.5)
61 (5.0)
257 (19.5)
326 (26.9)
32 (2.6)
68.2 ± 10.3
127 ± 18
25.6 ± 4.6
0.5 (0.2–1.8)
140 (11.5)
81 (6.7)
48 (4.0)
30 (2.5)
70 (5.8)
17 (1.4)
P-value
0.130
0.506
.
0.499
0.240
0.907
0.906
0.260
0.920
0.402
0.813
0.059
0.058
0.024
0.977
0.670
0.193
0.190
Secondary prevention subgroup 
(n=455)
Negative
345 (75.8)
61.6 ± 9.2
191 (55.4)
345 (100.0)
232 (67.3)
57 (16.5)
58 (21.5)
75 (21.7)
11 (3.2)
66.5 ± 10.6
136 ± 120
27.6 ± 5.0
3.1 (0.9–6.6)
178 (51.6)
149 (43.2)
86 (24.9)
48 (13.9)
69 (20.0)
22 (6.4)
Positive
110 (24.2)
60.0 ± 9.4
70 (63.6)
110 (0.0)
74 (67.3)
20 (18.2)
52 (28.1)
32 (29.1)
6 (5.5)
68.0 ± 9.6
136 ± 20
28.1 ± 5.2
2.8 (0.9–5.8)
51 (46.4)
42 (38.2)
33 (30.0)
13 (11.8)
18 (16.4)
5 (4.6)
P-value
0.099
0.127
.
0.996
0.686
0.105
0.113
0.275
0.170
0.972
0.396
0.546
0.339
0.354
0.292
0.574
0.398
0.479
Table 1: Clinical characteristics of the sample according to anti-
apoA-1 IgG status: A) general population, B) primary prevention and 
C) secondary prevention subgroups. Continuous data are expressed as 
mean ± standard deviation or median (interquartile range) according to the 
variable distribution. Categorical data are expressed as number of participants 
and (percentage). Statistical analysis by chi-square for categorical variables 
and Mann-Whitney U test for continuous variables. Anti-apoA-1 IgG, Autoanti-
bodies against Apolipoprotein A-1; BP; blood pressure; CVD, cardiovascular dis-
ease; SCORE, Systematic Coronary Risk Evaluation. The primary and secondary 
prevention subgroups are issued from the general study population.
Table 2: Odds ratio of anti-apoA-1 IgG for 
cardiovascular disease in unadjusted and 
adjusted models. Results are expressed as odds 
ratio (95 % confidence interval). Statistical analy-
sis was performed by multivariate logistic regres-
sion. The adjusted model was adjusted for age, 
sex, hypertension, diabetes, smoking, HDL choles-
terol and LDL cholesterol. Anti-apoA-1 IgG, auto-
antibodies against apolipoprotein A-1; OD, op-
tical density. * Subjects positive for anti-ApoA-1 
(OD≥0.64, n=1323) were divided into three 
groups of equal size and increasing anti-ApoA-1 
titres: 1st group (0.64≤OD<0.77), 2nd group 
(0.77≤OD<0.98) and 3rd group (OD≥0.98).
Positive anti-ApoA-1 IgG (OD≥0.64) vs 
negative (OD<0.64)
1SD change in OD levels
Anti-ApoA-1 IgG levels *
 Negative for anti-ApoA-1 IgG (OD<0.64)
 Positive for anti-ApoA-1 IgG (OD≥0.64) *
  1st group (0.64≤OD<0.77)
  2nd group (0.77≤OD<0.98)
  3rd group (OD≥0.98)
P-value for linear trend
Unadjusted 
model
OR (95 % CI)
1.31 (1.05–1.64)
1.15 (1.05–1.25)
1 (ref.)
1.02 (0.69–1.50)
1.24 (0.87–1.79)
1.68 (1.22–2.33)
0.002
P-value
0.018
0.003
0.936
0.236
0.002
Adjusted 
model
OR (95 % CI)
1.34 (1.05–1.70)
1.18 (1.07–1.30)
1 (ref.)
1.15 (0.76–1.74)
1.14 (0.76–1.70)
1.71 (1.21–2.42)
0.008
P-value
0.018
0.001
0.507
0.529
0.002
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crease for prevalent CVD per standard deviation increase in anti-
apoA-1 IgG values, which was also independent of established 
CVRFs (▶ Table 2). Finally, the association between presence of 
anti-apoA-1 IgG and CVD in the multivariate model remained 
unchanged after further adjusting for history of autoimmune dis-
ease as well as after excluding subjects with history of autoimmune 
disease (n=154) from the analysis.
Association between anti-apoA-1 IgG levels and 
 biological markers of CV risk
▶ Table 3 summarises variations in biological markers of CV risk, 
according to presence or absence of anti-apoA-1 IgG.
Subjects with elevated anti-ApoA-1 IgG levels tended to have 
lower serum levels of total cholesterol, HDL and magnesium 
than patients with low anti-apoA-1 IgG levels. No trends or sig-
nificant differences were observed for other lipid parameters, 
renal function, hs-CRP or uric acid between these two groups. 
Inverse and significant Spearman correlations were retrieved for 
anti-apoA-1 IgG and total cholesterol as well as anti-apoA-1 IgG 
and magnesium levels both in the general population (r=-0.05, 
p<0.001; r=-0.06, p<0.001, respectively) and in the primary pre-
vention subgroup (r=-0.05, p<0.001; r=-0.05, p<0.001, respect-
ively).
In the secondary prevention subgroup, patients with elevated 
anti-apoA-1 IgG levels presented significantly lower HDL and 
magnesium values, but higher hs-CRP and uric acid values than 
patients with low anti-apoA-1 IgG levels (▶ Table 3). Additionally, 
inverse significant Spearman correlations were observed between 
anti-apoA-1 IgG and HDL (r=-0.10, p=0.03) or anti-apoA-1 IgG 
and magnesium levels (r=-0.19; p<0.001), while significant posi-
tive correlations were found between anti-apoA-1 IgG and hs-CRP 
levels (r=0.11, p=0.02). The correlation for anti-apoA-1 IgG and 
uric acid levels was also positive (r=0.09; p=0.05). No other signifi-
cant correlations were observed between anti-apoA-1 IgG levels 
and biological parameters (data not shown). Notably, the negative 
association between anti-apoA-1 IgG and HDL levels remained 
robust after adjusting for statin treatment. Furthermore, no overall 
difference in the fractional excretion of magnesium in urine was 
found between subjects with presence vs absence of anti-apoA-1 
IgG, either in the general population or in the primary or second-
ary prevention subgroups (data not shown).
Anti-apoA-1 IgG
Sample size, n (%)
Lipids (mmol/l)
 Total cholesterol
 LDL cholesterol
 HDL cholesterol
 Triglycerides
Renal function
 eGFR, ml/min/1.73 m2
Serum ions (mmol/l)
 Magnesium
 Calcium
Surrogate markers of CVD
 Uric acid, µmol/l
 Homocysteine, µmol/l
 Hs-CRP, mg/l
General population 
(n=6649)
Negative
5326 (80.1)
5.59 ± 1.04
3.34 ± 0.92
1.63 ± 0.43
1.10
(0.8–1.6)
77.8
(69–88)
0.85 ± 0.07
2.29 ± 0.09
306
(251–365)
9.5
(7.9–11.7)
1.3
(0.6–2.7)
Positive
1323 (19.9)
5.53 ± 1.05
3.30 ± 0.92
1.62 ± 0.46
1.10
(0.8–1.6)
78.3
(68–89)
0.84 ± 0.07
2.28 ± 0.09
302
(249–365)
9.5
(7.8–11.6)
1.2
(0.6–2.8)
P-value
0.067
0.168
0.052
0.082
0.312
<0.001
0.103
0.689
0.596
0.588
Primary prevention subgroup 
(n=6194)
Negative
4981 (80.4)
5.60 ± 1.03
3.35 ± 0.91
1.64 ± 0.43
1.1
(0.8–1.6)
77.9
(69–88)
0.85 ± 0.07
2.28 ± 0.09
304
(249–363)
9.5
(7.9–11.5)
1.3
(0.6–2.7)
Positive
1213 (19.6)
5.55 ± 1.03
3.31 ± 0.91
1.63 ± 0.46
1.1
(0.8–1.5)
78.4
(69–89)
0.84 ± 0.07
2.28 ± 0.09
299
(247–358)
9.4
(7.7–11.4)
1.1
(0.6–2.5)
P-value
0.064
0.117
0.351
0.150
0.287
<0.001
0.120
0.173
0.198
0.082
Secondary prevention subgroup 
(n=455)
Negative
345 (75.8)
5.32 ± 1.04
3.13 ± 0.92
1.53 ± 0.42
1.3
(0.9–1.8)
76.2
(66–86)
0.84 ± 0.07
2.31 ± 0.09
335
(274–394)
10.2
(8.6–13.0)
1.6
(0.7–3.0)
Positive
110 (24.2)
5.35 ± 1.20
3.20 ± 1.01
1.40 ± 0.36
1.4
(1–2.1)
75.7
(66–91)
0.81 ± 0.07
2.30 ± 0.10
351
(299–415)
11.3
(9.0–14.4)
2.1
(1.2–5.0)
P-value
0.854
0.449
0.002
0.083
0.877
0.001
0.413
0.022
0.078
<0.001
Table 3: Biological characteristics of the sample according to anti-
apoA-1 IgG status: A) general population, B) primary prevention and 
C) secondary prevention subgroups. Data are expressed as mean ± stan-
dard deviation or median (interquartile range) according to the variable dis-
tribution. Statistical analysis was performed by Mann-Whitney test. Anti-
apoA-1 IgG, autoantibodies against apolipoprotein A-1; LDL, low-density li-
poprotein; HDL, high-density lipoprotein; eGFR, estimated glomerular fil-
tration rate (MDRD equation); CVD, cardiovascular disease; hs-CRP, high-sen-
sitivity C-reactive protein. The primary and secondary prevention subgroups 
are issued from the general study population.
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In a subgroup analysis performed specifically on coronary heart 
disease (CHD) patients (n=235), subjects with elevated anti-
apoA-1 IgG levels were more likely to present with metabolic syn-
drome and a higher basal heart rate when compared to patients 
with low anti-apoA-1 IgG levels (Suppl. Table 2, available online at 
www.thrombosis-online.com). Elevated levels of anti-apoA-1 IgG 
were also associated with significantly lower HDL and magnesium 
levels (p=0.015, p=0.004, respectively), and increased triglyceride 
(p=0.01) and hs-CRP levels (p=0.005) (Suppl. Table 3, available 
online at www.thrombosis-online.com).
Discussion
The main finding of the present large-scale study is the novel as-
sociation between anti-apoA-1 IgG and CVD in a population-
based sample, which is independent of established CVRF. Our re-
sults validate initial reports, which suggested that presence of these 
autoantibodies could be associated with prevalent CVD (14, 18), 
as well as CV complications in rheumatoid arthritis patients (13) 
and in high CV risk populations (19, 22, 23).
Furthermore, in this study we confirm that the presence of elev-
ated anti-apoA-1 IgG levels in secondary prevention patients is as-
sociated with a pro-inflammatory systemic profile (7–9, 13, 14, 
22), as reflected by lower HDL concentrations, but higher hs-CRP 
and uric acid levels. While different studies previously reported 
anti-apoA-1 IgG presence being associated with a loss of anti-athe-
rogenic properties of HDL due to decreased paraoxonase (PON) 
activity, in specific settings (9–12), this study is the first to indicate 
that elevated anti-apoA-1 IgG levels are inversely associated with 
HDL levels in subjects with established CVD, independently of 
statin treatment.
Because anti-apoA-1 IgG target the major protein component 
of HDL, the association between anti-apoA-1 IgG and lower HDL 
levels may be related to the clearance of immune anti-apoA-1 IgG 
and HDL complexes by the reticular-endothelial system. In ac-
cordance with this hypothesis, human case reports (33) described 
that patients with high anti-apoA-1 IgG levels entirely lacked ma-
ture HDL particles, suggesting decreased ability of pre-beta HDL 
to become lipidated, although additional mechanisms could also 
account for this finding. Along the same line, in a murine model of 
SLE, anti-apoA-1 IgG could lower HDL levels without affecting 
hepatic HDL biosynthesis, possibly by accelerating HDL clearance 
(12). On the other hand, anti-apoA-1 IgG passive immunisation in 
mice has not shown to impact HDL levels, despite otherwise 
marked effects on atherogenesis, myocardial necrosis and survival 
(8, 20), leaving the question open as to whether a causal link be-
tween apoA-1 IgG and HDL levels does exist. Lastly, the presence 
of these antibodies may also contribute to loss of HDL function by 
impairing ATP-binding cassette transporter A1 (ABCA1)-me-
diated cholesterol efflux or interfering with PON activity, although 
this assumption requires further experimental validation (9–12).
Association between anti-apoA-1 IgG levels and 
 biological markers of CV risk
The fact that patients with high anti-apoA-1 IgG levels had higher 
hs-CRP levels than patients without anti-apoA-1 IgG is in line 
with previous studies showing that elevated anti-apoA-1 IgG levels 
were associated with higher circulating levels of pro-inflammatory 
cytokines, including IL-6, TNF- alpha, myeloperoxidase, hs-CRP 
and matrix-metalloproteinase 9 (7, 13, 17, 20, 22). Because endot-
oxin-free anti-apoA-1 IgG was shown to induce a dose-dependent 
production of IL-6 and other inflammatory cytokines by human 
macrophages in a TLR2/CD14 dependent manner (7), a straight-
forward explanation for this association could be that the anti-
apoA-1 IgG-driven production of IL-6 by macrophages directly in-
duces CRP production by hepatocytes, a phenomenon highly de-
pendent on IL-6 stimulus (34, 35).
Another compelling finding of our study was that patients with 
high anti-apoA-1 IgG levels had significantly lower serum mag-
nesium concentrations compared to patients with low anti-apoA-1 
IgG levels. Previous studies showed anti-apoA-1 IgG to elicit in 
vitro a sustained positive chronotropic response on cardiomyo-
cytes through the activation of L-type calcium channels (24, 25), 
the activity of which is enhanced by intracellular magnesium defi-
ciency (26). Since magnesium depletion predisposes for cardiac ar-
rhythmias and CHD (36), this descriptive association could pro-
vide a model to support our previous observation that showed 
elevated anti-apoA-1 IgG levels after MI to be associated with a 
higher basal heart rate, as assessed by Holter monitoring (23). In-
terestingly, in the present study – apart from the difference in 
circulating concentrations of magnesium not previously assessed 
(23) – we found the same association between elevated anti-
apoA-1 IgG levels and basal heart rate in the subgroup of CHD pa-
tients. It is therefore plausible that the higher basal heart rate ob-
served in CHD patients with elevated anti-apoA-1 IgG levels could 
be mediated by concomitant lower magnesium concentrations, or 
that these patients have increased chronotropic susceptibility to 
relative hypomagnesaemia. Since the fractional excretion of mag-
nesium in the urine did not differ between subjects with high vs. 
low anti-apoA-1 IgG levels, one can reasonably exclude urinary 
magnesium wasting as the cause of this finding.
Prevalence of anti-apoA-1 IgG in the general 
 population
Our study raises an important question with regards to the preva-
lence of elevated anti-apoA-1 IgG levels in the general population. 
Indeed, while we were able to demonstrate that the prevalence of 
elevated anti-apoA-1 IgG levels was significantly higher in patients 
with CVD than in those without (using the same ELISA protocol 
and the same definition of elevated anti-apoA-1 IgG levels as in 
our previous studies), the overall prevalence of elevated anti-
apoA-1 IgG levels in the CoLaus study approached 20 %, whereas 
previously reported values varied between 0 to 6.5 % for healthy 
blood donors or matched controls (14, 17, 21) and between 
11–29 % for subjects in secondary prevention (Suppl. Table 4, 
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available online at www.thrombosis-online.com) (19, 22, 23). The 
reasons for such a discrepancy are not fully understood, although 
one could argue that due to stringent selection criteria, healthy 
blood donors may not be representative of the general population 
(37). In addition, sample size may play a role since this is the first 
large-scale study of anti-apoA-1 IgG in the community. Fur-
thermore, as only baseline anti-apoA-1 IgG levels were measured, 
we could not assess potential variations of anti-ApoA-1 IgG levels 
over time (38) and especially after cardiovascular events, a point 
that will need to be determined in future studies.
Strengths and limitations
The strength of our study lies in its unbiased, community-based 
approach that enabled us to confirm that elevated anti-apoA-1 IgG 
are independently associated with CVD in a large and extensively 
characterised sample of the general population.
There are several limitations to this study. First, owing to the 
observational and cross-sectional nature of the data, a causal rela-
tionship between anti-ApoA-1 IgG and CVD cannot be firmly es-
tablished. This hypothesis is currently being tested in an ongoing 
longitudinal study aiming at exploring the prognostic value of 
anti-ApoA-1 IgG in the general population.
Secondly, apart from anti-ApoA-1 IgG titres, we did not have 
data on other clinically relevant autoantibodies, such as anti-ox-
idised LDL, anti-phospholipid or anti-nuclear antibodies. Previous 
work demonstrated that presence of anti-apoA-1 IgG was inde-
pendent of the existence of other autoantibodies (such as anti-
oxLDL, anti-phosholipid, anti-nuclear, anti-heat shock protein 
antibodies) and provided the strongest prognostic accuracy for 
CVD, especially after MI (23, 39). However, further studies are 
required to challenge these preliminary results.
Moreover, we did not measure apoA-1 levels nor did we assess 
the possible qualitative changes in HDL, such as PON1 activity, re-
verse cholesterol efflux capacity or HDL anti-inflammatory prop-
erties. As apoA-1 is largely responsible for reverse cholesterol 
transport and stabilisation of PON1 (40), it is plausible that anti-
apoA-1 IgG could decrease apoA-1 levels, rendering the protein 
less able to promote cholesterol efflux and thereby manifest its 
anti-atherogenic effects. We assume that both apoA-1 levels and 
HDL functional properties would be altered in anti-apoA-1 IgG 
positive patients, as reported earlier (11); however, we did not col-
lect data to challenge this hypothesis.
Lastly, it remains elusive as to whether elevated anti-apoA-1 
IgG levels are associated with susceptibility to infections. Previous 
studies reported that polyclonal human anti-apoA-1 IgG response 
is focused against epitopes present on the C-terminal part of 
apoA-1 (41, 42). Since the latter shares structural homologies with 
TLR2 (7), it is suggested that pathogen molecular mimicry may be 
the underlying mechanism for the deleterious properties of these 
autoantibodies. The design of this study did not allow for the ex-
ploration of association between the existence of anti-apoA-1 IgG 
and previous exposure to specific pathogens.
Conclusion
The present study confirms that elevated anti-apoA-1 IgG levels 
are independently associated with CVD in the general population, 
while also being associated with CV biomarkers in patients with a 
history of CVD. Prospective studies are needed to evaluate the 
prognostic value of anti-apoA-1 IgG as a biomarker for CVD in 
the general population as well as to investigate the possible thera-
peutic value of developing immune therapies directed against anti-
apoA-1 IgG.
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Background: Autoantibodies against apolipoprotein A-1 (anti-apoA-1 IgG) have 
emerged as an independent biomarker for cardiovascular disease and mortality. 
However, their association with all-cause mortality in the community, as well as their 
genetic determinants, have not been studied.
Objective: To determine whether anti-apoA-1 IgG: (a) predict all-cause mortality in the 
general population and (b) are associated with single-nucleotide polymorphisms (SNPs) 
in a genome-wide association study (GWAS).
Methods: Clinical, biological, and genetic data were obtained from the population-based, 
prospective CoLaus study, including 5,220 participants (mean age 52.6 years, 47.3% 
men) followed over a median duration of 5.6 years. The primary study outcome was 
all-cause mortality.
Results: After multivariate adjustment, anti-apoA-1 IgG positivity independently pre-
dicted all-cause mortality: hazard ratio (HR)  =  1.54, 95% confidence interval (95% 
CI): 1.11–2.13, P = 0.01. A dose–effect relationship was also observed, each SD of 
logarithmically transformed anti-apoA-1 IgG being associated with a 15% increase in 
mortality risk: HR = 1.15, 95% CI: 1.02–1.28, P = 0.028. The GWAS yielded nine SNPs 
belonging to the Fc receptor-like 3 (FCRL3) gene, which were significantly associated 
with anti-apoA-1 IgG levels, with the lead SNP (rs6427397, P = 1.54 × 10−9) explaining 
0.67% of anti-apoA-1 IgG level variation.
Conclusion: Anti-apoA-1 IgG levels (a) independently predict all-cause mortality in 
the general population and (b) are linked to FCRL3, a susceptibility gene for numerous 
autoimmune diseases. Our findings indicate that preclinical autoimmunity to anti-apoA-1 
IgG may represent a novel mortality risk factor.
Keywords: autoimmunity, autoantibodies, apolipoprotein A-1, mortality, genome-wide association study, 
Fc receptor-like 3
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INTRODUCTION
Autoimmune diseases (ADs) represent a major health issue 
affecting up to 10% of the population (1–4). Multiple studies 
have established the relationship between a chronic inflamma-
tory state due to clinical or quiescent autoimmunity and poor 
outcomes in various clinical settings (5, 6). Marking sustained 
B-cell activation, presence of autoantibodies specifically rep-
resents a signature of humoral autoimmunity, which can drive 
disease pathogenesis even in the absence of overt clinical AD 
(7–9).
More than a decade ago, early clinical studies have sup-
ported the role of autoantibodies against apolipoprotein A-1 
(anti-apoA-1 IgG), the principal component of high-density 
lipoproteins (HDLs), as mediators of chronic low-grade inflam-
mation and predictors of unfavorable outcomes in patients 
with ADs (10–17). Subsequently, in  vitro and animal studies 
demonstrated the ability of these autoantibodies to elicit a pro-
inflammatory and pro-atherogenic response through interac-
tion with the TLR2/TLR4/CD14 complex, followed by NF-κB 
and MAPK downstream activation as the main molecular 
pathway (18–24).
Recently, due to these pro-inflammatory and pro-atherogenic 
properties, anti-apoA-1 IgG gained interest as independent 
biomarkers for incident cardiovascular (CV) disease (CVD) and 
mortality, as well as potential therapeutic targets for immune-
modulating interventions, in high CV risk populations (16, 19, 
20, 22, 25–28). Moreover, similar to what has been reported 
with other autoantibodies (7), our group recently demonstrated 
that elevated anti-apoA-1 IgG levels were present in up to 20% 
of individuals in the general population and associated with 
prevalent CVD independently of traditional CV risk factors 
(25). Nevertheless, the association of anti-apoA-1 IgG with 
all-cause mortality in the general population has not yet been 
studied.
From another point of view, while rare autoimmunity 
syndromes can result from monogenic mutations, common 
human ADs are complex disorders arising from the interaction 
between polygenic and environmental risk factors, disrupting 
mechanisms of immune tolerance. In recent years, genome-wide 
association studies (GWASs) have provided insight into the subtle 
immune dysregulation caused by common genetic variants that 
predispose to clinical autoimmunity (29, 30) and autoantibody 
production in particular (31–34).
Although the risk attributable to most of the identified 
individual nucleotide variants is modest, modern GWAS have 
the potential to provide an unbiased view of biological pathways 
that drive autoimmunity (1–4). However, despite the associations 
of anti-apoA-1 IgG with adverse outcomes in different patient 
populations, no study has so far investigated common genetic 
variants potentially related to their serum values.
Thus, the goal of the present study was twofold. We aimed to 
determine whether anti-apoA-1 IgG: (a) predict all-cause mortal-
ity in the general population in a prospective study and (b) are 
associated with single-nucleotide polymorphisms (SNPs) in a 
GWAS.
METHODS
Study Population and Design
Clinical and biological data were obtained from the CoLaus 
study, a population-based prospective cohort of 6,733 partici-
pants recruited between 2003 and 2006 in the city of Lausanne, 
Switzerland. Of the initial baseline sample of 6,733 participants, 
5,220 (mean age 52.6 ± 10.7 years, 47.3% men) had complete 
clinical and biological data over a median follow-up (FU) time 
of 5.6  years and were included in the prospective analysis. A 
detailed description of the study design, variables, and sampling 
procedures has been reported elsewhere (35).
All participants attended the outpatient clinic of the University 
Hospital of Lausanne. Clinical data and fasting venous blood 
samples were collected from each participant by trained field 
interviewers during a single visit lasting about 60 min. Blood 
pressure and heart rate were measured three consecutive times 
using an automated sphygmomanometer (Omron® HEM-907, 
Matsusaka, Japan), and the average of the last two measurements 
was used. Body weight and height were measured with partici-
pants standing without shoes in light indoor clothes. Body weight 
was measured in kilograms to the nearest 100 g using a Seca® 
scale, and height was measured to the nearest 5 mm using a Seca® 
height gauge. Body mass index (BMI) was calculated as weight 
(kg)/height (m2). Hypertension was defined as a systolic blood 
pressure ≥140 mm Hg and/or a diastolic blood pressure ≥90 mm 
Hg and/or the presence of anti-hypertensive treatment. Diabetes 
mellitus was defined as fasting plasma glucose ≥7.0 mmol/l and/
or oral or insulin anti-diabetic treatment. History of CVD was 
defined by the presence of myocardial infarction, angina pectoris, 
percutaneous revascularization or bypass grafting for ischemic 
heart disease, and stroke or transient ischemic attack and assessed 
according to standardized medical records (35). History of ADs 
was obtained via questionnaire. Estimated glomerular filtration 
rate (eGFR) was calculated by the simplified “Modification of Diet 
in Renal Disease” prediction equation. Absolute risk for CVD 
was computed using the Systematic Coronary Risk Evaluation 
algorithm (36).
Venous blood samples were drawn after an overnight fast, 
and assays were performed on fresh plasma samples within 2 h 
of blood collection for standard lipid profile and on unthawed 
serum aliquots for anti-apoA-1 IgG determination, (see below) 
that were immediately processed and stored at −80°C. Standard 
lipid profile was performed by the CHUV Clinical Laboratory 
using a Modular P apparatus (Roche Diagnostics, Switzerland). 
The following analytical procedures (with maximum inter- and 
intra-batch CVs) were used: total cholesterol by the “CHOD-
PAP” method (1.6–1.7%); HDL cholesterol by the “CHOD-PAP/
PEG/Cyclodextrin” method (3.6–0.9%); triglycerides by the 
“GPO-PAP” method (2.9–1.5%); glucose by glucose dehydro-
genase (2.1–1.0%); and serum creatinine by the Jaffe kinetic 
compensated method (2.9–0.7%).
Determination of Anti-apoA-1 IgG Levels
Autoantibodies against apolipoprotein A-1 were measured 
as previously described (19, 22, 37), using the CoLaus study 
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(2003–2006) frozen serum aliquots, stored at −80°C. Maxisorp 
plates (Nunc™, Denmark) were coated with purified, human-
derived delipidated apolipoprotein A-1 (20 µg/ml; 50 µl/well) 
for 1  h at 37°C. After being washed, all wells were blocked 
for 1 h with 2% bovine serum albumin (BSA) in a phosphate 
buffer solution (PBS) at 37°C. Participants’ samples were also 
added to a non-coated well to assess individual non-specific 
binding. After six washing cycles, a 50  µl/well of signal 
antibody (alkaline phosphatase-conjugated anti-human IgG; 
Sigma-Aldrich, St. Louis, MO, USA), diluted 1:1,000 in a 
PBS/BSA 2% solution, was added and incubated for 1  h at 
37°C. After washing six more times, phosphatase substrate 
p-nitrophenyl phosphate disodium (Sigma-Aldrich) dissolved 
in a diethanolamine buffer (pH 9.8) was added and incubated 
for 20 min at 37°C (Molecular Devices™ Versa Max). Optical 
density (OD) was determined at 405 nm, and each sample was 
tested in duplicate. Corresponding non-specific binding was 
subtracted from mean OD for each sample. The specificity of 
detection was assessed using conventional saturation tests by 
Western blot analysis.
As previously described (19, 22, 37), elevated levels of anti-
apoA-1 IgG were set at an OD cut-off of OD >0.64, correspond-
ing to the 97.5th percentile of a reference population of 140 
healthy blood donors. In order to limit the impact of inter-assay 
variation, we further calculated an index consisting in the ratio 
between sample net absorbance and the positive control net 
absorbance × 100. The index value corresponding to the 97.5th 
percentile of the normal distribution was 37. Accordingly, to 
be considered as positive (presenting elevated anti-apoA-1 IgG 
levels), samples had to display both an absorbance value >0.64 
OD and an index value ≥37%.
Genome-Wide Association Study
Genotyping was performed using the Affymetrix GeneChip® 
Human Mapping 500K array set and genotypes were called 
using BRLMM. SNPs with a call rate <70% and individuals with 
call rate <90% were excluded from further analysis. Participants 
found to be of non-European ancestry by principal component 
analysis of the genotype data were also excluded, leaving 5,402 
participants eligible for GWAS. Imputation was performed using 
IMPUTE version 0.2.0 and CEU haplotypes from HapMap 
release 21. The dataset used for imputation consisted in 390,631 
genotyped SNPs with a call rate >0.9, Hardy–Weinberg P-value 
>10−7, and MAF >1%.
Before performing the GWAS, anti-apoA-1 IgG levels were 
adjusted for age, sex, and ancestry principal components. The 
residuals were then inverse normal quantile transformed and 
regressed onto genetic allele dosages. To fine map the genome-
wide significant association at the FCRL2/3 locus, we re-imputed 
the 400-kb window around the top HapMap-associated SNP 
using haplotypes from the HRC reference panel.
Study Endpoints
The primary study endpoint was overall mortality, but specific 
causes of death were also considered. All deaths and related causes 
were adjudicated by an independent panel of internal medicine 
physicians, blinded to all study variables.
Statistics
Statistical analyses were conducted using Stata v14.1 (Stata 
Corp., TX, USA) and MatLab v8.3 (MathWorks, MA, USA). 
Bivariate analysis of continuous variables was performed 
using Student’s or Mann–Whitney test as appropriate, while 
analysis of categorical variables was performed using chi-
square test. The association of anti-apoA-1 IgG levels with 
all-cause mortality was assessed by the log-rank test and by 
Cox proportional hazards regression, adjusting for age, gender, 
hypertension, diabetes, smoking, BMI, eGFR, HDL and low-
density lipoprotein (LDL) cholesterol, baseline CVD, and AD. 
Anti-apoA-1 IgG concentrations were natural log transformed 
to account for skewed distributions, and results were expressed 
as hazard ratios (HRs) and 95% confidence intervals (95% CIs). 
Considering a two-sided alpha of 0.05, our study had 80% 
power to detect a relative risk for all-cause mortality of 1.45 
in participants positive for anti-apoA-1 IgG. All tests were 
two tailed, and P values <0.05 were considered as statistically 
significant.
RESULTS
Figure 1A shows the participants’ selection procedure, and Table 
S1 in Supplementary Material summarizes the baseline charac-
teristics of participants, with or without FU data. Overall, subjects 
lost at FU were more likely to be smokers, hypertensive, obese, 
and with a less favorable lipid profile than subjects included in 
the analysis, but did not differ with regards to anti-apoA-1 IgG 
positivity or serum levels.
During FU, 191 deaths (3.7%) occurred. The three major causes 
of death were cancer, CVD, and infectious diseases. Participants 
who died presented with a significantly higher prevalence of 
anti-apoA-1 IgG positivity (26.7 vs. 19.6%, P  =  0.016) and 
higher anti-apoA-1 IgG levels (median [interquartile range]: 0.43 
[0.30–0.70] vs. 0.39 [0.25–0.59] AU, P = 0.007), than participants 
alive at FU (Table 1). Of note, median anti-apoA-1 IgG values 
of anti-apoA-1 IgG-positive subjects who died at FU were 0.89 
[0.79–1.05] AU.
Kaplan–Meier curves for participants with positive and nega-
tive anti-apoA-1 IgG titers are shown in Figure 1B; participants 
positive for anti-apoA-1 IgG had higher mortality rates than 
participants negative for the marker (4.9 vs. 3.4%, log-rank 
P = 0.034). Conversely, 95.1% of anti-apoA-1 IgG-positive sub-
jects survived, compared to 96.6% of anti-apoA-1 IgG-negative 
subjects corresponding to an absolute survival difference of 1.5% 
between the two groups.
Cox regression analysis indicated that anti-apoA-1 IgG posi-
tivity was associated with a 1.5-fold increased risk of death, and 
this hazard rate remained unchanged after adjustment for the 
aforementioned mortality risk factors, including baseline CVD 
and AD: HR = 1.54 (1.11–2.13), P = 0.01. Similarly, 1 SD increase 
of the log-transformed anti-apoA-1 IgG levels was associated 
with a 15% increase in the risk of all-cause mortality: HR = 1.15 
(1.02–1.28), P = 0.028 (Table 2). Sensitivity analyses excluding 
participants with CVD or AD at baseline led to comparable find-
ings (Table 2).
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FIGURE 1 | (A) Participants’ selection procedure. (B) Kaplan–Meier curves for all-cause mortality, according to autoantibodies against apolipoprotein A-1 
(anti-apoA-1 IgG) status. P-value according to log-rank test (P = 0.034).
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TABLE 1 | Baseline characteristics of the sample according to all-cause 
mortality during follow-up.
Overall 
(n = 5,220)
Survivors 
(n = 5,029)
Non-
survivors 
(n = 191)
P-value
Age, years 52.6 ± 10.7 52.2 ± 10.6 62.7 ± 9.5 <0.001
Male sex, n (%) 2,461 (47.3) 2,337 (46.6) 124 (64.9) <0.001
History of CVD, n (%) 379 (7.3) 337 (6.7) 42 (22.0) <0.001
Current smoking, n (%) 1,356 (26.1) 1,277 (25.5) 79 (41.4) <0.001
Diabetes, n (%) 326 (6.3) 282 (5.6) 44 (23.0) <0.001
BMI (kg/m2) 25.6 ± 4.4 25.6 ± 4.4 26.7 ± 5.5 <0.001
Hypertension, n (%) 1,723 (33.1) 1,613 (32.2) 110 (57.6) <0.001
SBP (mmHg) 127.6 ± 17.7 127.2 ± 17.6 135.3 ± 19.1 <0.001
eGFR (ml/min/1.73 m2) 78.7 ± 15.7 78.8 ± 15.5 75.4 ± 20.0 0.014
Total cholesterol 
(mmol/l)
5.56 ± 1.02 5.57 ± 1.01 5.53 ± 1.19 0.625
HDL cholesterol 
(mmol/l)
1.64 ± 0.44 1.64 ± 0.44 1.54 ± 0.47 0.001
LDL cholesterol (mmol/l) 3.32 ± 0.91 3.32 ± 0.90 3.26 ± 1.02 0.362
Triglycerides (mmol/l) 1.37 ± 1.14 1.36 ± 1.06 1.78 ± 2.33 <0.001
SCORE risk (%) 2.08 ± 3.57 1.91 ± 3.35 6.01 ± 5.80 <0.001
Known AD (RA, SLE) 115 (2.2) 110 (2.2) 5 (2.6) 0.696
Anti-apoA-1 IgG 
positivity
1,035 (19.9) 984 (19.6) 51 (26.7) 0.016
Anti-apoA-1 IgG levels 
(AU)
0.39 [0.34] 0.39 [0.33] 0.43 [0.40] 0.007
Incident overall death 
rate, n (%)
191 (3.7) 191 (3.7)
Cancer-related, n (%) 69 (36.1) 69 (36.1)
CVD-related, n (%) 36 (18.9) 36 (18.9)
Infectious-related, n (%) 25 (13.1) 25 (13.1)
Other causesa, n (%) 51 (26.7) 51 (26.7)
Undetermined, n (%) 10 (5.2) 10 (5.2)
P values are derived from the comparison of patients with low vs. high levels of 
anti-apoA-1 IgG. Variables are expressed as mean ± SD or median [interquartile 
range] as appropriate or number of participants and percentage. Statistical analysis 
for continuous variables was performed by Student’s t-test or Mann–Whitney test 
depending on the normality assumption. Chi-squared test was used for categorical 
variables.
AD, autoimmune disease; CVD, cardiovascular disease; SBP, systolic blood pressure; 
eGFR, estimated glomerular filtration rate according to the MDRD formula; HDL, 
high-density lipoprotein; LDL, low-density lipoprotein; RA, rheumatoid arthritis; 
SLE, systemic lupus erythematosus; SCORE, Systematic Coronary Risk Evaluation; 
AU, arbitrary units of optical density; BMI, body mass index; anti-apoA-1 IgG, 
autoantibodies against apolipoprotein A-1.
aOther causes include lung disease (n = 12), bleeding and trauma-related 
complications (n = 11), suicide (n = 9), chronic renal failure (n = 6), non-ischemic heart 
failure (n = 5), chronic liver failure (n = 5), and dementia (n = 3).
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Genome-wide association study on anti-apoA-1 IgG levels 
identified a single locus located in chromosome 1 (157.6–
157.9  Mb) including 21 SNPs significantly associated with 
anti-apoA-1 IgG levels (Figure 2A; Table S2 in Supplementary 
Material). The T allele of the lead SNP (rs6427397) was associ-
ated with an increase of anti-apoA-1 IgG levels by 0.113 AU and 
explained 0.67% of anti-apoA-1 IgG variation. Conversely, in 
logistic regression (yes vs. no anti-apoA-1 IgG positivity) analy-
sis, the T allele of rs6427397 had an odds ratio (OR) of 1.27 (95% 
CI 1.15–1.40) for anti-apoA-1 IgG positivity in our sample. The 
20 remaining SNPs identified in the same region were in strong 
linkage disequilibrium and associated with anti-apoA-1 levels 
at P-value <10−7 (Figure 2B). Most of these SNPs were located 
in or near the Fc receptor-like 2 (FCRL2) and 3 (FCRL3) genes 
and to some extend in the regions spanning the FCRL1 gene 
(Figures 2B,C). SNPs with a previously known biological func-
tion or association with a clinical trait were located in the FCRL3 
gene (Table S2 in Supplementary Material). Additionally, the only 
coding polymorphism among the identified SNPs represents a 
missense variant (rs7522061) also located in the FCRL3 gene. 
We also observed an association between anti-apoA-1 IgG and 
a missense variant (rs1047989) in the human leukocyte antigen 
(HLA)-DQA1 gene, which did not, however, achieve stringent 
genome-wide significance (P = 7.27 × 10−7, data not shown).
DISCUSSION
This is the first study to demonstrate that anti-apoA-1 IgG levels 
are significantly and independently associated with all-cause 
mortality in the general population. In our population, after 
5 years of FU, 95.1% of anti-apoA-1-positive subjects survived, 
compared to 96.6% of anti-apoA-1-negative participants. This 
corresponds to a modest, nevertheless, significant (P =  0.03) 
absolute survival difference of 1.5% between the two groups.
Our results extend previous findings (19, 22, 25, 26) and sug-
gest that preclinical autoimmunity against apoA-1/HDL—which 
affects up to one-fifth of the general population—may identify 
individuals at increased risk of death. Our findings raise the 
possibility that presence of anti-apoA-1 IgG leads to pathophysi-
ological events affecting not only CV prognosis, but also survival 
in the long term. Based upon previous studies, such events could 
be related to a chronic low-grade inflammatory state through 
sustained activation of the TLR2/TLR4/CD14 complex and 
production of pro-inflammatory cytokines (14, 18, 21, 24, 38), 
associations with elevated high-sensitivity C-reactive protein and 
uric acid levels (23, 25), impairment of HDL function (10–13, 16, 
17), interference with basal heart rate regulation (22, 24, 25) or 
B-cell epitope spreading (39). Other pathophysiological mecha-
nisms, other than those currently ascribed to anti-apoA-1 IgG 
could also be involved, in the same way that multiple molecular 
pathways underlie the associations of other autoantibodies with 
all-cause mortality in the community (7, 9, 40, 41). These chal-
lenging points will have to be investigated in future clinical and 
translational research efforts.
The second notable finding of our study is that anti-apoA-1 
IgG levels are related to genetic polymorphisms belonging or 
regulating the FCRL3 gene. Indeed, our lead SNP (rs6427397) is 
an intergenic variant that represents a strong expression quantita-
tive trait loci for the FCRL3 gene in whole blood (1.2 × 10−12) 
(42). Additionally, among the 20 remaining FCRL SNPs achieving 
genome-wide significance, the only coding variant identified 
(rs7522061) is a missense variant of the FCRL3 gene.
Fc receptor-like genes are located in the human chromosome 
regions 1q21–23 and belong to the immunoglobulin genes super-
family. FCRL3 in particular is known to encode a mature B-cells 
co-receptor primarily expressed in secondary lymphoid organs 
and involved in B  cell maturation, regulation, and production 
of autoantibodies (43–45). Previous work suggests that FCRL3 
expression further affects T  regulatory cells development and 
function, with high expression resulting in abnormal immune 
activation and breakdown of self-tolerance (46). Corroborating 
TABLE 2 | Association between anti-apoA-1 IgG and all-cause mortality.
Events (n) Unadjusted HR
HR (95% CI)
P-value Adjusted HRa
HR (95% CI)
P-value
Overall sample (n = 5,220)
 – High vs. low levels
 – For 1 SD increase in log (anti-apoA-1 IgG)
191
191
1.41 (1.02–1.95)
1.14 (1.01–1.28)
0.035
0.040
1.54 (1.11–2.13)
1.15 (1.02–1.30)
0.010
0.028
Participants without CVD at baseline (n = 4,825)
 – High vs. low levels
 – For 1 SD increase in log (anti-apoA-1 IgG)
149
149
1.42 (0.98–2.04)
1.14 (0.99–1.31)
0.062
0.062
1.62 (1.12–2.34)
1.19 (1.03–1.38)
0.011
0.019
Participants without AD at baseline (n = 5,105)
 – High vs. low levels
 – For 1 SD increase in log (anti-apoA-1 IgG)
186
186
1.42 (1.02–1.97)
1.15 (1.01–1.30)
0.036
0.030
1.68 (1.21–2.34)
1.23 (1.07–1.40)
0.002
0.002
Data are expressed as adjusted HRs and 95% CI. Statistical analysis by Cox proportional hazards regression.
AD, autoimmune disease; HR, hazard ratio; CVD, cardiovascular disease; 95% CI, 95% confidence interval; anti-apoA-1 IgG, autoantibodies against apolipoprotein A-1.
aAdjusted for age, sex, hypertension, diabetes, smoking, high- and low-density lipoprotein cholesterol, body mass index, estimated glomerular filtration rate baseline CVD and AD.
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these in vivo findings, large-scale GWAS have identified FCRL3-
related SNPs as major susceptibility genes for numerous ADs in 
humans (44, 47, 48).
The observed association of FRCL3 with anti-apoA-1 IgG 
values in our sample is in line with previous studies showing that 
two-thirds of candidate loci for autoimmunity discovered by 
GWAS represent shared risk factors for multiple ADs (1, 3, 49). 
Among potential pathophysiological mechanisms, FCRL3 may 
predispose to clinical autoimmunity by pleiotropic regulation of 
the production of other deleterious autoantibodies. FCRL3 has 
been associated with the production of cyclic citrullinated pep-
tide autoantibodies in rheumatoid arthritis (RA) (47) and anti-
bodies to thyroid peroxidase in patients suffering from Graves’ 
disease (33). In a study of genetic determinants of autoantibody 
production in over 8,000 type 1 diabetes cases, Plagnol et al. 
(31) identified the FCRL3 locus to be associated with antibodies 
against insulinoma-associated antigen 2 concluding that FCRL3 
“may have general effects in adaptive immunity, in the complex 
interactions between antigen presenting cells and T cells lead-
ing to antibody producing plasma B cells.” Unfortunately, we 
were unable to measure in our sample other antibodies, such as 
anti-oxidized LDL, antiphospholipid, antinuclear, or anti-heat 
shock protein antibodies in order to test this hypothesis.
Finally, with regards to anti-apoA-1 IgG and CV disease and 
mortality (19, 20, 22), FCRL3 mRNA levels have been reported 
to be downregulated in patients with myocardial infarction when 
compared to those with stable angina or healthy subjects (50), 
suggesting that FCRL3-mediated immune dysregulation may also 
be involved in atheromatous plaque instability and rupture.
Although statistically significant, the effect of the T allele of 
the lead SNP (rs6427397) on autoantibody levels was modest 
[OR 1.27 (95% CI 1.15–1.40)] and explained 0.67% of total anti-
apoA-1 IgG variation. This is not surprising since incremental 
effect sizes of genetic variants are rather common in genetic stud-
ies of autoimmunity where most risk alleles have ORs less than 
1.2 (29, 30, 32) in spite of their low performance regarding disease 
prediction, these risk variants may provide important etiological 
information based on associated genomic regions, that could 
lead to a more sophisticated understanding of the molecular 
pathways underlying common ADs. Thus, genetic signatures of 
susceptibility to autoimmunity could provide a basis for assess-
ing heterogeneity in disease progression, in response to targeted 
immune-modulating interventions, as well as for rational novel 
drug design.
The fact that the lead SNP in our study relates to an intergenic 
non-coding variant in the FCRL3 locus is in accordance with 
current evidence from high-density genotyping and epigenomic 
studies which demonstrate that in common ADs, up to 90% 
of identified causal variants appear to be non-coding, while 
60% correspond to immune cell enhancers (3). The current 
paradigm supports the notion that intergenic regions are densely 
populated with hundreds of thousands of regulatory elements 
that modulate cell type-specific gene expression (1, 3). In a study 
on RA (47), Kochi et al. demonstrated that non-coding SNPs 
in the promoter region of FCRL3 have a regulatory effect on 
expression of the FCRL3 gene and relate to augmented autoan-
tibody production in subjects with the susceptible genotype. In 
the same line of thought, our present results indicate that the 
sequence of events leading to high of anti-apoA-1 IgG levels 
could be related to an impaired regulation of gene expres-
sion programs—including FCRL3—a hypothesis that requires 
further study.
Finally, although we did not retrieve any strictly genome-wide 
significant association between anti-apoA-1 IgG and HLA-related 
genes, we did observe an association trend at P = 7.27 × 10−7 that 
may represent a clinically meaningful signal in future studies and 
further relates the presence of these autoantibodies to autoim-
munity susceptibility genes.
Study limitations are worth noting. First, our genetic analysis 
was conducted in a single population sample, including only indi-
viduals of Caucasian ancestry and will require further validation 
in independent cohorts, ideally involving other ethnic groups. 
Since genetic data on anti-apoA-1 IgG are so far inexistent, 
we were unable to identify a replication cohort for our GWAS. 
Nevertheless, our findings represent the first attempt to identify 
the genetic determinants of anti-apoA-1 IgG. Second, as the spe-
cific functionality of T allele of rs6427397 is currently unknown, 
we can only so far extrapolate on the pathophysiological 
FIGURE 2 | (A) Manhattan plot of the genome-wide association analysis for autoantibodies against apolipoprotein A-1 (anti-apoA-1 IgG) levels. The x-axis is 
chromosomal position and the y-axis is the significance (−log P; two-tailed) of association derived by the linear regression. The red line represents genome-wide 
significance level (p = 5 × 10−8) that was achieved by a single locus located in chromosome 1. (B) Regional plot at the Fc receptor-like (FCRL)2/3 locus on 
chromosome 1 showing single-nucleotide polymorphism (SNP) association strength for anti-apoA-1 IgG levels. To fine map the genome-wide significant association 
at the FCRL2/3 locus, we re-imputed the 400-kb window around the top HapMap-associated SNP using haplotypes from the HRC reference panel. −log10 P 
values (y-axis) are presented according to their chromosomal positions (x-axis). The index SNP in the analysis (i.e., SNP with the smallest P-value, rs6427397, 
purple diamond) and the only coding SNP identified (rs7522061) are labeled. The color intensity of each symbol reflects their linkage disequilibrium (r2) values with 
the index SNP, red (r2 > 0.8) through to navy blue (r2 < 0.2). Genes in each region, direction of transcription, and genomic coordinates are shown at the bottom. (C) 
Quantile–quantile plot of SNPs for anti-apoA-1 IgG levels. The negative logarithm of the observed (y-axis) and the expected (x-axis) P-value is plotted for each SNP 
(dot). The black lines indicate the null hypothesis of no true association (x = y) with 95% confidence intervals. Significant deviation from the expected (null) P-value 
distribution is evident only in the upper tail area (blue line), corresponding to SNPs with the strongest association.
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relevance of the reported association, as related to regulation 
of the FCRL3 gene. Indeed, the only genome-wide significant 
coding variant identified (rs7522061) is a missense variant of 
the FCRL3 gene. As we only measured baseline anti-apoA-1 IgG 
levels, we were not able to assess the dynamic of anti-apoA-1 
IgG levels over time in relation with mortality. Knowing whether 
an increase of anti-apoA-1 IgG would precede clinical events or 
whether our findings could be affected by transient anti-apoA-1 
IgG positivity in a single sample will be important to determine 
in future studies.
Similarly, one could argue that since the actual difference in 
anti-apoA-1 IgG levels between the survivors and non-survivors 
was modest, these results are unlikely to be clinically relevant even 
though the relative observed difference in anti-apoA-1 IgG values 
is 9.3% and statistically significant in our sample (P = 0.007), 
as expected from sample power calculation. The fact that the 
distribution of anti-apoA-1 IgG values is positively skewed (25) 
and that low CV risk participants are known to present lower 
levels of anti-apoA-1 IgG than high CV risk subjects (19, 22, 
25) could explain these relatively low anti-apoA-1 IgG values in 
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the general population, despite significant differences between 
survivors and non-survivors. Finally, the observed anti-apoA-1 
IgG values translates in a 19.9% anti-apoA-1 IgG positivity in the 
sample, which is similar to the reported prevalence of other IgG 
autoantibodies in the community (7).
Despite these limitations, our study provides—to our best 
knowledge—the first evidence of a significant association of 
anti-apoA-1 IgG with all-cause mortality and a major AD 
susceptibility gene. Although our findings are in accordance 
and extending previous results, they will need to be replicated 
in independent, adequately powered, prospective cohorts before 
any conclusion on potential clinical implications can be drawn.
CONCLUSION
Our study suggests that anti-apoA-1 IgG levels predict all-cause 
mortality in the general population and are associated with a 
single locus involving FCRL3, a gene known to predispose for 
ADs. Our findings indicate that preclinical autoimmunity to 
apoA-1 may identify a substantial proportion of individuals 
at increased risk of death in the general population, a finding 
that will need further validation in independent, prospective 
cohorts.
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Major discoveries in the pathophysiology of atherosclerosis have established the fundamental role of a chronic inflam-
matory state in the initiation, progression, and—finally—rupture 
of the atherosclerotic plaque.1 During the last decade, humoral 
autoimmunity and autoantibodies have been recognized as 
important modulators of vascular inflammation and atherogen-
esis.2 Autoantibodies can be active mediators in the development 
of coronary artery disease (CAD)3,4 and, as such, serve as bio-
markers for the prediction of incident CAD5–9 and as potential 
biological targets amenable to immunomodulatory therapies.
Recently, the atherogenic role of autoantibodies against 
apoA-1 (apolipoprotein A-1; anti-apoA-1 IgG), the principal 
protein component of high-density lipoprotein (HDL), has 
been investigated in clinical studies, showing that anti-apoA-1 
IgG are associated with prevalent and incident CAD in sub-
jects with autoimmune diseases,5 subjects at high cardiovas-
cular risk6,10 or after myocardial infarction,4,7 independently 
of established cardiovascular risk factors. Furthermore, we 
recently showed that anti-apoA-1 IgG are present in up to one 
fifth of individuals in the general population and independently 
© 2017 American Heart Association, Inc.
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Objective—We aimed to determine whether autoantibodies against apoA-1 (apolipoprotein A-1; anti-apoA-1 IgG) predict 
incident coronary artery disease (CAD), defined as adjudicated incident myocardial infarction, angina, percutaneous 
coronary revascularization, or bypass grafting, in the general population. We further investigated whether this association 
is modulated by a functional CD14 receptor single nucleotide polymorphism.
Approach and Results—In a prospectively studied, population-based cohort of 5220 subjects (mean age 52.6±10.7 years, 
47.4% males), followed over a median period of 5.6 years, subjects positive versus negative for anti-apoA-1 IgG presented 
a total CAD rate of 3.9% versus 2.8% (P=0.077) and a nonfatal CAD rate of 3.6% versus 2.3% (P=0.018), respectively. 
After multivariate adjustment for established cardiovascular risk factors, the hazard ratios of anti-apoA-1 IgG for total 
and nonfatal CAD were: hazard ratio=1.36 (95% confidence interval, 0.94–1.97; P=0.105) and hazard ratio=1.53 (95% 
confidence interval, 1.03–2.26; P=0.034), respectively. In subjects with available genetic data for the C260T rs2569190 
single nucleotide polymorphism in the CD14 receptor gene (n=4247), we observed a significant interaction between anti-
apoA-1 IgG and rs2569190 allele status with regards to CAD risk, with anti-apoA-1 IgG conferring the highest risk for 
total and nonfatal CAD in non-TT carriers, whereas being associated with the lowest risk for total and nonfatal CAD in 
TT homozygotes (P for interaction =0.011 and P for interaction =0.033, respectively).
Conclusions—Anti-apoA-1 IgG are independent predictors of nonfatal incident CAD in the general population. The 
strength of this association is dependent on a functional polymorphism of the CD14 receptor gene, a finding suggesting 
a gene–autoantibody interaction for the development of CAD.
Visual Overview—An online visual overview is available for this article.  (Arterioscler Thromb Vasc Biol. 2017;37: 
2342-2349. DOI: 10.1161/ATVBAHA.117.309602.)
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associated with prevalent CAD,11 as well as with all-cause 
mortality.12 Nevertheless, their predictive value for incident 
CAD in the general population has not yet been studied.
From a pathophysiological point of view, in vitro and in vivo 
studies have demonstrated that anti-apoA-1 IgG per se behave as 
proinflammatory, proarrhythmogenic, and prothrombotic mol-
ecules, promoting atherogenesis, myocardial necrosis, and death 
in mice.4,13 Based on previous published studies, such events 
could be related to a chronic low-grade inflammatory state,3,14,15 
associations with elevated high-sensitivity C-reactive protein and 
increased uric acid levels,11 impairment of HDL antiatherogenic 
properties,16–18 interference with basal heart rate regulation,7,11,15 
or breakdown of self-tolerance.12 However, the main patho-
physiological mechanism—reported to date—underpinning the 
pathogenicity of anti-apoA-1 IgG is their interaction with innate 
immune system receptors and the activation of the TLR (Toll-
like receptor)2/TLR4/CD14 complex.14,19 In particular, the cur-
rent paradigm suggests that because of molecular mimicry of the 
C-terminal part of ApoA-1 to TLR2, anti-apoA-1 IgG bind to 
the TLR2/TLR4 complex and require a functional CD14 recep-
tor for effective intracellular signaling, NF-κB (nuclear factor-
κB) and MAPK (mitogen-activated protein kinase) downstream 
activation, and production of proinflammatory cytokines.13
These findings point to CD14 receptor, the canoni-
cal ligand of lipopolysaccharide, as a major effector of the 
anti-apoA-1 IgG deleterious properties. A functional single 
nucleotide polymorphism at position C260T (rs2569190) of 
the CD14 receptor gene has been shown to modulate its tran-
scriptional activity.20,21 Among the 3 groups of CD14 geno-
types for rs2569190 (CC, CT, or TT), TT carriers seem to be 
protected from CD14 ligand-induced inflammation because 
of a better ability to adequately control the lipopolysaccha-
ride-mediated TLR/CD14-dependent immune response.22–24 
Indeed, previous studies demonstrated that TT carriers were 
less at risk for gram-negative bacterial infection and sepsis 
death25,26 for developing heart failure,27 as well as atherosclero-
sis,28–30 although this latter observation is debated.31 However, 
whether TT carriers are also less susceptible to anti-apoA-1 
IgG–related atherosclerosis has not been examined.
Thus, our current study had 2 main aims: first, we inves-
tigated whether anti-apoA-1 IgG predict incident CAD in the 
general population. Second, because of the anti-apoA-1 IgG 
role as a danger-associated molecular pattern, specifically 
activating CD14-related pathways,4,13 we further examined 
whether the functional C260T rs2569190 polymorphism in 
the CD14 receptor gene modulates the anti-apoA-1 IgG–
related CAD risk, hypothesizing a protective effect associated 
with carriage of the T allele.
Materials and Methods
Materials and Methods, including characterization analyses related 
to anti-apoA-1 IgG assay validation, are available in the online-only 
Data Supplement.
Results
Association Between Anti-apoA-1 
IgG and Incident CAD
Figure 1 demonstrates the flowchart of the study. Of the initial 
6733 participants, 5220 had complete clinical and biological 
data over a median follow-up (FU) time of 5.6 years and were 
included in the final sample. Participants who did not partici-
pate in FU (21.6%) were more likely to be smokers, hyperten-
sive, overweight with a less favorable lipid profile, compared 
with those included in the analysis. There were no significant 
differences in anti-apoA-1 IgG levels or prevalence of anti-
apoA-1 IgG positivity between the 2 groups (Table I in the 
online-only Data Supplement).
Table 1 provides baseline characteristics of the final sam-
ple according to anti-apoA-1 IgG status. Overall, cardiovas-
cular risk factors were equally distributed between subjects 
with positive versus negative anti-apoA-1 IgG titers. Among 
the 157 subjects who developed CAD during FU, 132 had a 
Nonstandard Abbreviations and Acronyms
Anti-apoA-1 IgG anti-apolipoprotein A-1 autoantibodies
CAD  coronary artery disease
FU  follow-up
HDL  high-density lipoprotein
HR  hazard ratio
TLR  toll-like receptor
Figure 1. Study flowchart. Anti-apoA-1 IgG indicates autoanti-
bodies against apolipoprotein A-1; CAD, coronary artery disease; 
and FU, follow-up.
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nonfatal event and 25 a fatal one. Total incident CAD rate was 
3.9% versus 2.8% (P=0.077), while nonfatal incident CAD 
rate was 3.6% versus 2.3% (P=0.018) for subjects with posi-
tive versus negative anti-apoA-1 IgG titers. No significant dif-
ferences were observed with regards to fatal incident CAD.
Table 2 summarizes hazard ratios (HR) for the associa-
tion of anti-apoA-1 IgG with total, nonfatal, and fatal incident 
CAD. In unadjusted models, we retrieved a trend between 
anti-apoA-1 IgG positivity and total incident CAD (HR, 1.39; 
95% confidence intervals (CI), 0.97–1.99; P=0.073) that 
remained unchanged after adjusting for sex, age, smoking 
status, diabetes mellitus, systolic blood pressure, low-density 
lipoprotein and HDL cholesterol, baseline CAD, statin and 
β-blocker treatment, and estimated glomerular filtration rate 
(HR, 1.36; 95% CI, 0.94–1.97; P=0.105). The HRs of 1 SD 
increase in log-transformed anti-apoA-1 IgG values for total 
incident CAD were HR, 1.11 (95% CI, 0.96–1.28; P=0.159) 
and HR, 1.09 (95% CI, 0.94–1.27; P=0.232) in the unadjusted 
and adjusted analyses, respectively. Levels of anti-apoA-1 
IgG above optical density >0.98 (third tertile) were signifi-
cantly associated with total incident CAD in the unadjusted 
(HR, 1.79; 95% CI, 1.09–2.95; P=0.021) and the adjusted 
analysis (HR, 1.70; 95% CI, 1.03–2.81; P=0.038).
Furthermore, anti-apoA-1 IgG positivity was significantly 
associated with nonfatal incident CAD both in the unadjusted 
(HR, 1.58; 95% CI, 1.08–2.31; P=0.018) and the adjusted 
analysis (HR, 1.53; 95% CI, 1.03–2.26; P=0.034). Similarly 
to what was observed for total incident CAD, the HRs of 1 
SD increase in log-transformed anti-apoA-1 IgG values for 
nonfatal CAD were as follows: HR, 1.15 (95% CI, 0.99–1.34; 
P=0.072) and HR, 1.14 (95% CI, 0.97–1.33; P=0.109) in the 
unadjusted and adjusted analyses, respectively. Anti-apoA-1 
IgG levels above optical density >0.98 (third tertile) were 
strongly associated with nonfatal incident CAD both in the 
unadjusted (HR, 2.21; 95% CI, 1.34–3.67; P=0.002) and the 
adjusted model (HR, 2.14; 95% CI, 1.29–3.56; P=0.003; 
Table 2). On the contrary, no associations were observed 
between anti-apoA-1 IgG positivity or tertiles with fatal inci-
dent CAD. Sensitivity analyses after exclusion of subjects 
with baseline CAD or autoimmune disease yielded similar 
results for the associations between anti-apoA-1 IgG and 
total, nonfatal, and fatal CAD (Table II in the online-only 
Data Supplement). Additionally, statistical analyses after 
excluding adjustment for statin and β-blocker treatment or 
estimated glomerular filtration rate from the fully adjusted 
model yielded similar results (Table III in the online-only 
Data Supplement).
Interaction Between C260T 
rs2569190 Polymorphism and Anti-
apoA-1 IgG for Incident CAD
Among genotyped subjects (n=4247; Figure 1), we further 
investigated whether the functional C260T rs2569190 poly-
morphism in the CD14 receptor gene modulates anti-apoA-1 
IgG–related CAD risk. Subjects with missing genetic data 
tended to have a lower burden of cardiovascular risk factors 
and a higher prevalence of anti-apoA-1 IgG positivity (Tables 
IV and V in the online-only Data Supplement).
Characteristics of the genotyped sample according to the 
C260T rs2569190 polymorphism allele status are illustrated 
in Table VI in the online-only Data Supplement. All cardiovas-
cular risk factors were equally distributed among subgroups, 
with the exception of an increased prevalence of diabetes mel-
litus and statin treatment in the TT subgroup. Importantly, the 
C260T rs2569190 polymorphism per se was not associated 
with total, nonfatal, or fatal incident CAD, all-cause mortal-
ity, or anti-apoA-1 IgG positivity (Table VI in the online-only 
Data Supplement).
Table 1. Characteristics of the Sample, According to Anti-
apoA-1 IgG Status
Total Sample (n=5220)
Anti-apoA-1 IgG
P Value
Absence 
(n=4180)
Presence 
(n=1040)
Age, y 52.7±10.7 52.2±10.7 0.184
Male sex, n (%) 1985 (47.5) 488 (46.9) 0.744
History of CAD, n (%) 146 (3.5) 43 (4.1) 0.321
Current smoking, n (%) 1086 (26.0) 272 (26.2) 0.909
Diabetes mellitus, n (%) 276 (6.6) 58 (5.6) 0.226
Hypertension, n (%) 1389 (33.23) 349 (33.6) 0.841
Autoimmune disease, n (%) 88 (2.1) 32 (3.1) 0.061
Body mass index, kg/m2 25.6±4.4 25.7±4.6 0.712
Total cholesterol, mmol/L 5.58±1.02 5.50±1.03 0.022
HDL cholesterol, mmol/L 1.64±0.43 1.62±0.46 0.250
LDL cholesterol, mmol/L 3.33±0.90 3.27±0.92 0.068
Triglycerides, mmol/L 1.38±1.12 1.36±1.22 0.663*
SCORE CV risk categories, n (%)
  Low risk 2507 (60.1) 643 (62.0)  
  Intermediate risk 1160 (27.8) 269 (25.9)  
  High risk 311 (7.4) 83 (8.0)  
  Very high risk 196 (4.7) 43 (4.1) 0.487
CV drugs, n (%)
  Aspirin 684 (16.4) 160 (15.4) 0.443
  Statins 446 (10.7) 98 (9.4) 0.239
  Beta blockers 212 (5.1) 70 (6.7) 0.034
  Calcium-channel blockers 120 (2.9) 33 (3.2) 0.605
  ACEi/ARB 511 (12.2) 124 (11.9) 0.354
  Diuretics 80 (1.9) 19 (1.8) 0.854
  Incident CAD rates, n (%) 117 (2.8) 40 (3.9) 0.077
  Nonfatal, n (%) 95 (2.3) 37 (3.6) 0.018
  Fatal, n (%) 22 (0.5) 3 (0.3) 0.320
Data are expressed as mean±standard deviation or number of participants 
and (percentage). ACEi indicates angiotensin-converting enzyme inhibitor; Anti-
apoA-1 IgG, anti-apolipoprotein A-1 autoantibodies; ARB, angiotensin receptor 
blockers; CAD, coronary artery disease; CV, cardiovascular; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein; SCORE, Systematic Coronary Risk 
Evaluation.
*Statistical analysis for continuous variables by student’s t test or Mann–
Whitney test depending on the normality assumption. Statistical analysis for 
categorical variables by the χ2 test.
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To assess differences in anti-apoA-1 IgG–related CAD 
risk according to the C260T rs2569190 polymorphism, we 
created both an additive (CC versus CT versus TT), as well 
as a recessive (CC/CT versus TT) model and performed a sta-
tistical test for the interaction32 between anti-apoA-1 IgG and 
carriage of the T allele for total and nonfatal incident CAD 
risk. As previously, all analyses were adjusted for sex, age, 
smoking status, diabetes mellitus, systolic blood pressure, 
low-density lipoprotein and HDL cholesterol, baseline CAD, 
statin and β-blocker treatment, and estimated glomerular fil-
tration rate.
In the case of the additive model (CC versus CT versus 
TT), we observed a gradient of risk for anti-apoA-1 IgG with 
regards to CAD across the 3 predefined C260T rs2569190 
subgroups (Table 3). Specifically, in the subgroup homozygote 
for the major allele (CC, n=1097), the adjusted anti-apoA-1 
IgG HR for total CAD was HR, 2.27 (95% CI, 1.04–4.97; 
P=0.039), while it was HR, 1.52 (95% CI, 0.86–2.71; 
P=0.152) in the heterozygote subgroup (CT, n=2095) and 
HR, 0.55 (95% CI, 0.19–1.61; P=0.275) in the minor allele 
subgroup (TT, n=1055). Results were similar with regards 
to the recessive (CC/CT versus TT) model. Notably, in non-
TT carriers—representing 75.1% of the cohort—anti-apoA-1 
IgG positivity conferred a 1.8-fold risk for total CAD (HR, 
1.77; 95% CI, 1.12–2.80; P=0.014; Table 3), while change 
per 1 SD in anti-apoA-1 values yielded a HR of 1.11 (95% 
CI, 0.92–1.34; P=0.285) for total CAD in the fully adjusted 
model. Results were similar with regards to nonfatal incident 
CAD (Table 3).
Testing for the interaction between anti-apoA-1 IgG and 
C260T rs2569190 polymorphism with respect to CAD in 
the fully adjusted analysis indicated that the observed gradi-
ent in anti-apoA-1 IgG–related CAD risk across the differ-
ent CD14 genotype subgroups in the additive (CC versus CT 
versus TT) model was statistically significant for both total 
and nonfatal CAD risk (P for interaction =0.011 and P for 
interaction =0.033, respectively; Table 3), proving substantial 
heterogeneity in anti-apoA-1 IgG–related CAD risk according 
to T allele carriage. A forest plot summarizes these findings 
(Figure I in the online-only Data Supplement). Furthermore, 
statistical analyses after excluding adjustment for statin and 
β-blocker treatment or estimated glomerular filtration rate 
from the fully adjusted model yielded similar results (Table 
VII in the online-only Data Supplement).
Figure 2 describes Kaplan–Meier curves for total and 
nonfatal CAD according to anti-apoA-1 IgG positivity and 
C260T rs2569190 allele status. Participants positive for anti-
apoA-1 IgG (Figure 2A and 2B) presented an increased risk 
for total and nonfatal CAD compared with those negative 
for anti-apoA-1 IgG. After splitting the positive anti-apoA-1 
IgG group according to homozygous or not carriage of the 
T allele (CC/CT versus TT), a decrease in the proportion 
of total and nonfatal CAD was observed in the anti-apoA-1 
IgG–positive TT subgroup (Figure 2C and 2D, green line), 
falling below the rate of CAD observed in anti-apoA-1 IgG–
negative subjects (Figure 2C and 2D, blue line). Conversely, 
higher proportion of total and nonfatal CAD was observed 
in anti-apoA-1 IgG–positive non-TT carriers (Figure 2C 
and 2D, black line) when compared with anti-apoA-1 IgG–
positive subjects as a whole (Figure 2C and 2D, red line, 
log-rank: P=0.023 and P=0.017 for total and nonfatal CAD, 
respectively).
Table 2. Hazard Ratios of Anti-apoA-1 IgG for Incident Total, Nonfatal, and Fatal CAD in the General Population
n=5220
Total Incident CAD (n=159) Nonfatal Incident CAD (n=134) Fatal Incident CAD (n=25)
Unadjusted 
Model
P 
Value
Adjusted 
Model
P 
Value
Unadjusted 
Model
P 
Value
Adjusted 
Model
P 
Value
Unadjusted 
Model
P 
Value
Adjusted 
Model
P 
Value
Positive vs negative 1.39  
(0.97–1.99)
0.073
1.36  
(0.94–1.97)
0.105
1.58  
(1.08–2.31)
0.018
1.53  
(1.03–2.26)
0.034
0.54  
(0.16–1.80)
0.313
0.56  
(0.17–1.91)
0.356
1 SD change in log-
transformed anti-ApoA-1 
IgG levels
1.11  
(0.96–1.28)
0.159
1.09  
(0.94–1.27)
0.232
1.15  
(0.99–1.34)
0.072
1.14  
(0.97–1.33)
0.109
0.88  
(0.61–1.29)
0.520
0.87  
(0.60–1.27)
0.474
Anti-ApoA-1 IgG levels*
  Negative (OD<0.64) 1 (ref.)  1 (ref.)  1 (ref.)  1 (ref.)  1 (ref.)  1 (ref.)  
  First tertile 
(0.64<OD≤0.77)
1.18  
(0.64–2.19)
0.597
1.39  
(0.74–2.59)
0.879
1.32  
(0.69–2.53)
0.406
1.50  
(0.78–2.89)
0.227
0.60  
(0.08–4.43)
0.613
0.75  
(0.96–5.92)
0.788
  Second tertile 
(0.77<OD≤0.98)
1.16  
(0.63–2.16)
0.633
0.95  
(0.48–1.88)
0.879
1.17  
(0.59–2.33)
0.646
0.89  
(0.41–1.93)
0.767
1.02  
(0.24–4.37)
0.974
1.13  
(0.26–4.90)
0.872
  Third tertile 
(OD>0.98)
1.79  
(1.09–2.95)
0.021
1.70  
(1.03–2.81)
0.038
2.21  
(1.34–3.67)
0.002
2.14  
(1.29–3.56)
0.003 No subjects No subjects
  P value for linear 
trend
0.047  0.160  0.012   0.021   
Results are expressed as adjusted hazard ratios and (95% confidence interval) for subjects positive (OD>0.64) vs negative (OD<0.64) for anti-apoA-1 IgG. Statistical 
analysis by Cox proportional hazards regression adjusted for age, sex, systolic blood pressure, diabetes mellitus, smoking, HDL and LDL cholesterol, baseline CAD, 
statin, β-blocker treatment, and eGFR. Anti-apoA-1 IgG indicates anti-apolipoprotein A-1 autoantibodies; CAD, coronary artery disease; eGFR, estimated glomerular 
filtration rate; HDL, high density lipoprotein; LDL, low density lipoprotein; OD, optical density; and SD, standard deviation.
*Subjects with positive Anti-ApoA-1 (n=1040) were divided in tertiles (n=347) of increasing titers: first tertile (0.64<OD<0.77), second tertile (0.77<OD<0.98), and 
third tertile (OD>0.98).
 by guest on December 13, 2017
http://atvb.ahajournals.org/
Downloaded from 
2346  Arterioscler Thromb Vasc Biol  December 2017
Discussion
The main finding of the present study is that anti-apoA-1 IgG 
are independently associated with nonfatal incident CAD 
in the general population, with the anti-apoA-1 IgG–related 
CAD risk being strongly modulated by the C260T rs2569190 
CD14 gene polymorphism. Indeed, after taking CD14 single 
nucleotide polymorphisms into account, we observed a signif-
icant anti-apoA-1 IgG–related CAD risk gradient, dependent 
on carriage of the C260T rs2569190 T allele, with non-TT 
carriers being at significantly increased risk for both total and 
nonfatal CAD compared with TT homozygotes. Our results 
extend current knowledge not only in the field of anti-apoA-1 
IgG but also in the field of personalized CAD prediction in 
different ways.
First, similarly to what has been shown in high-risk popu-
lations,5–7,33 our current findings argue that anti-apoA-1 IgG 
positivity is an independent predictor of poor CV outcome in 
the general population, supporting the notion that preclinical 
autoimmunity to apoA-1 may identify a substantial proportion 
of individuals at increased risk of CAD. In our study, anti-
apoA-1 IgG–related CAD risk was highest in subjects car-
rying at least one C allele (CC/CT) in the functional C260T 
rs2569190 polymorphism, a group that represents roughly 3 
quarters of White populations.31 By virtue of being the first 
study on a gene–autoantibody interaction with respect to 
CAD, our analysis highlights the importance of incorporating 
genetic data on immune-related polymorphisms when evalu-
ating anti-apoA-1 IgG–related risk and provides insight for 
future study design on individualized CAD prediction.
Second, these results represent a human validation of the 
key role of CD14 coreceptor in mediating the anti-apoA-1 IgG 
proatherogenic properties as demonstrated to date in animal 
and in vitro models4,13 and reinforce the relevance of these pre-
clinical results to the anti-apoA-1 IgG–associated CAD risk in 
humans. Conversely, in line with a recent meta-analysis,31 our 
findings are equivocal and do not provide definite evidence 
with regards to the association between TT genotype carriage 
and CAD risk.
Third, our data highlight the importance of considering the 
individual genetic information on innate immune receptors for 
proper assessment of CAD risk associated with biomarkers of 
humoral autoimmunity. To the best of our knowledge, none of 
the genetic studies published to date took into account biomark-
ers (including autoantibodies) for CAD risk prediction, and 
none of the publications exploring the auto-antibodies–asso-
ciated CAD risk prediction evaluated the impact of individual 
genetic background on such risk. By demonstrating a poten-
tially important gene–environment interaction between anti-
apoA-1 IgG and the CD14 receptor gene in the pathogenesis of 
atherosclerosis, our findings may explain the discordant find-
ings regarding both the role of CD14 polymorphisms in CAD 
prediction31 and the contrasting results of humoral auto-autoim-
munity in CAD risk assessment.33 Overall, our results provide 
a proof-of-concept that combining genetic data together with 
serum biomarkers is likely to be required for the implementa-
tion of precision medicine in the field of CAD prediction.
In our study, the fact that TT carriers were less at risk 
to develop anti-apoA-1 IgG–related CAD compared with 
Table 3. Hazard Ratios of Anti-apoA-1 IgG for Incident Total, Nonfatal, and Fatal CAD According to the C260T rs2569190 
Polymorphism Allele Status, in the Genotyped Population
Anti-apoA-1 IgG, HR (95% 
CI), for CAD
Total Incident CAD (n=132) Nonfatal Incident CAD (n=109) Fatal Incident CAD (n=23)
Unadjusted 
Model
P 
Value
Adjusted 
Model
P 
Value
Unadjusted 
Model
P 
Value
Adjusted 
Model
P 
Value
Unadjusted 
Model
P 
Value
Adjusted 
Model
P 
Value
C260T rs2569190 allele status
  CC (n=1097) 2.08  
(0.98–4.42)
0.056
2.27  
(1.04–4.97)
0.039
2.19  
(0.98–4.87)
0.055
2.38  
(1.03–5.51)
0.042
1.39  
(0.14–13.42)
0.773
1.55  
(0.15–15.81)
0.713
  CC/CT (n=3192) 1.67  
(1.07–2.60)
0.023
1.77  
(1.12–2.80)
0.014
1.84  
(1.14–2.95)
0.012
1.95  
(1.19–3.19)
0.008
0.91  
(0.26–3.17)
0.880
0.90  
(0.24–3.32)
0.877
  CT (n=2095) 1.55  
(0.89–2.68)
0.120
1.52  
(0.86–2.71)
0.152
1.75  
(0.96–3.16)
0.066
1.73  
(0.93–3.23)
0.084
0.76  
(0.17–3.43)
0.718
0.54  
(0.10–3.00)
0.486
  TT (n=1055) 0.58  
(0.20–1.65)
0.306
0.55  
(0.19–1.61)
0.275
0.74  
(0.25–2.14)
0.573
0.74  
(0.25–2.22)
0.592 No subjects  No subjects  
P value for interaction 
between anti-apoA-1 IgG 
and rs2569190 (CC vs CT 
vs TT)
 0.064  0.011  0.135  0.033  NA  NA
P value for interaction 
between anti-apoA-1 IgG 
and rs2569190 (CC/CT 
vs TT)
 0.068  0.020  0.126  0.047  NA  NA
Results are expressed as adjusted hazard ratios and (95% confidence interval) for subjects positive (OD>0.64) vs negative (OD<0.64) for anti-apoA-1 IgG. Statistical 
analysis by Cox proportional hazards regression adjusted for age, sex, systolic blood pressure, diabetes mellitus, smoking, HDL and LDL cholesterol, baseline CAD, 
statin, β-blocker treatment, and eGFR. The P value for interaction represents the likelihood of interaction between the C260T rs2569190 allele status and the relative 
anti-apoA-1 IgG effect for coronary artery disease. Anti-apoA-1 IgG indicates anti-apolipoprotein A-1 autoantibodies; CAD, coronary artery disease; CI, confidence 
interval; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HR, hazard ratio; LDL, low density lipoprotein; and OD, optical density.
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non-TT carriers, despite TT homozygote status being pre-
viously associated with a higher systemic inflammatory 
profile,20,21 merits mention. To this respect, several lines of 
evidence indicate that TT genotype could confer protection 
against uncontrolled inflammatory response evoked by long-
term danger-associated molecular pattern exposure through 
different and mutually nonexclusive mechanisms. First, previ-
ous studies indicate that in the context of chronic low-grade 
CD14/TLR4 stimulation, the higher levels of sCD14 ascribed 
to the TT genotype inhibit systemic lipopolysaccharide-medi-
ated inflammatory responses by downregulating inflammatory 
cytokines transcription34,35 and facilitating CD14-related dan-
ger-associated molecular pattern clearance,24 thus, protecting 
TT carriers against sustained inflammatory responses through 
a negative feedback mechanism. Inversely, lower levels of 
sCD14 observed in CC carriers have been shown to favor vas-
cular wall inflammation and atherogenesis through impaired 
plasma clearance of endotoxin.22,23 C-allele carriers may be 
less able to prevent anti-apoA-1 IgG–mediated CD14/TLR4 
activation, resulting in maintenance of a proatherogenic state 
and a higher risk for developing CAD.28–30 Finally, increased 
expression of CD14 on the vascular endothelium of TT homo-
zygotes35 could also play a protective role in atherogenesis, 
in response to CD14 ligands such as anti-apoA-1 IgG.22,23,34,35
Several study limitations are noteworthy. First, although 
great effort was undertaken to maximize the participation 
rate during FU, our results may be subject to attrition bias 
as dropout rate after mean duration of 5.6 years was ≈20%. 
Nevertheless, similar losses in FU are commonly reported 
in prospective cohorts36 and are within the conventional par-
ticipation rate thresholds for cohort studies.37 Second, we 
did not directly measure sCD14 in study subjects to confirm 
the presumed higher sCD14 levels in TT homozygote car-
riers reported previously. Moreover, as our assay assesses 
Figure 2. Kaplan–Meier curves for cumulative incident coronary artery disease. Top, Kaplan–Meier curves for cumulative (A) total and (B) 
nonfatal incident CAD according to anti-apoA-1 IgG status (red line, positive for anti-apoA-1 IgG; blue line, negative for anti-apoA-1 IgG). 
Bottom, Kaplan–Meier curves for cumulative (C) total and (D) nonfatal incident CAD according to anti-apoA-1 IgG and C260T rs2569190 
allele status (black line, positive for anti-apoA-1 IgG and carrying the C allele (CC/CT); green line, positive for anti-apoA-1 IgG and car-
rying the T allele (TT); blue line, negative for anti-apoA-1 IgG). Data are expressed as the cumulative proportion of the sample presenting 
with incident CAD (y axis) during study years (x axis). Statistical analysis by Log rank test, for the comparison between anti-apoA-1 IgG 
negative subjects (blue line) vs anti-apoA-1 IgG positive-TT carriers (green line) vs anti-apoA-1 IgG positive-non-TT carriers (black line). 
Anti-apoA-1 IgG indicates autoantibodies against apolipoprotein A-1; and CAD, coronary artery disease.
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anti-apoA-1IgG antibodies against native apoA-1,19,38 we 
were not able to measure antibodies against modified forms 
of apoA-1, such as oxidized apoA-1 (or possibly glycated 
and carbamylated apoA-1). Because these modified forms of 
apoA-1 were shown to be of relevance for HDL functionality 
and the pathology of atherosclerosis,39–41 knowing whether 
they would elicit a humoral response clinically relevant to 
human physiopathology is still unclear. Third, because of 
sample availability, we only measured baseline anti-apoA-1 
IgG levels and did not assess the dynamic of anti-apoA-1 IgG 
levels over time in relation with incident CAD. Moreover, 
we could not test other clinically relevant antibodies, such 
as anti-oxidized low-density lipoprotein, anti-phospholipid, 
antinuclear or antiheat shock protein antibodies, which 
would have been instrumental to better understanding poten-
tial associations with innate immune receptor–related genes 
of interest. Finally, sample size calculation in our study was 
performed with regards to the primary outcome of detect-
ing a difference in incident CAD in subjects positive versus 
negative for anti-apoA-1 IgG. Although the fact that previ-
ous evidence suggested an interaction between anti-apoA-1 
IgG and the CD14 receptor and that we were able to detect 
such a—significant—interaction between anti-apoA-1 IgG 
and the functional C260T rs2569190 polymorphism in the 
CD14 receptor gene, it is possible that the current sample 
size provided <80% power for this secondary study out-
come. Therefore, this finding requires replication in larger 
prospective studies.
In conclusion, anti-apoA-1 IgG levels are independent 
predictors of incident nonfatal CAD in the general popula-
tion. The strength of this association is significantly modu-
lated by the functional C260T rs2569190 single nucleotide 
polymorphism in the CD14 receptor gene, being the high-
est in non-TT carriers and the lowest in TT homozygotes. 
These results imply that preclinical autoimmunity to apoA-1 
should be evaluated carefully as it may help to improve the 
identification of individuals at increased risk of CAD in the 
general population, especially in non-TT carriers represent-
ing ≈75% of the population. Our findings indicate that gene–
autoantibodies interaction studies are likely to be required to 
better assess the CAD risk related to humoral autoimmunity 
biomarkers in the general population, a concept that requires 
further investigation.
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Highlights
• Anti-apoA-1 (apolipoprotein A-1) IgG are independent predictors of nonfatal incident coronary artery disease in the general population.
• Anti-apoA-1 IgG could represent a potential novel target for immune-modulating preventive strategies for coronary artery disease.
• The strength of the association between anti-apoA-1 IgG and coronary artery disease is dependent on a functional polymorphism of the CD14 
receptor gene.
• Our findings suggesting a gene–autoantibody interaction for the development of CAD, an observation that requires further study.
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